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ABSTRACT 
 
The innate immune system has the ability to tune the inflammatory environment by 
modulating pathogen-recognition receptors (PRRs) signaling, which can either induce oncogenic 
changes or generate antitumor immunity through cross-talking with adaptive immunity. Thus, tight 
regulation of innate immune signaling pathways is essential either for an effective immune 
response against viral infections and tumor or for preventing detrimental autoimmunity.  
Mitochondrial antiviral-signaling protein MAVS acts as a central hub for RIG-I receptor 
proximal signal propagation. However, key components in the assembly of the MAVS 
mitochondrial platform that promote RIG-I mitochondrial localization and optimal activation are 
still largely undefined. Employing pooled RNAi and yeast two-hybrid screenings, we report that 
the mitochondrial adaptor protein TRIM14 provides a docking platform for the assembly of the 
mitochondrial signaling complex required for maximal activation of RIG-I-mediated signaling, 
consisting of WHIP and protein phosphatase PPP6C. Following viral infection, the ubiquitin-
binding domain in WHIP bridges RIG-I with MAVS through the binding to polyUb chains of RIG-
I at lysine 164. ATPase domain in WHIP contributes to the stabilization of RIG-I-dsRNA 
interaction. Moreover, phosphatase PPP6C is responsible for RIG-I dephosphorylation. Together, 
our findings define the WHIP-TRIM14-PPP6C mitochondrial signalosome required for RIG-I-
mediated innate antiviral immunity. 
Giving the embryonic lethality of Beclin1 (Becn1) homozygous mice, roles of myeloid 
Becn1 in cancer-associated inflammation and tumor immunity remain elusive. We demonstrate 
herein that mice with myeloid loss of Becn1 (Becn1ΔM) show high risk of precursor (pre)-B cell 
lymphoma associated with neutrophilia. Becn1 deficiency stabilizes neutrophil MEKK3 
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independent of autophagy, resulting in the aberrant p38 activation and exaggerated tumorigenic 
inflammation that triggers the expressions of PD-L1 and pro-survival genes in pre-B cells. 
Importantly, we identify low Becn1 expression of neutrophils correlates with programmed death 
ligand 1 (PD-L1) levels and cancer recurrence in patients with pre-B acute lymphoblastic 
lymphoma (ALL). In a mouse model of melanoma, expansion and infiltration of neutrophils and 
B cells due to Becn1 deficiency favor metastasis of B16 melanoma. Thus, homeostatic 
maintenance of Becn1 level in neutrophils will contribute to the outcome of the tumorigenic 
process of pre-B cells.  
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
Innate sensing at the interface of immunity and cancer 
Sensing of pathogen infection or tissue damage/injury by pattern recognition receptors 
(PRRs) of the host innate immune system triggers the activation or cross-activation of type I IFN, 
nuclear factor-κB (NF-κB), Mitogen-activated protein kinase (MAPK), and inflammasomes, 
leading to the production of pro-inflammatory cytokines [1, 2]. Rapid termination of the immune 
response by negative feedback inhibition protects the host from cytokine storm but also the viral 
immune-evasion mechanisms of the co-evolution of viruses with hosts [3]. Toll-like, Nod-like, 
RIG-like, AIM2-like, C-type lectin, OAS-like receptors are the primary cellular sensors and 
germline-encoded PRRs expressed not only in professional innate immune cells (i.e., macrophages, 
dendritic cells, etc.) but also in majority of non-hematopoietic cells epithelial cells, fibroblasts and 
endothelial cells [1]. Innate sensing is important for the defense of infection and sounds alarms 
when environmental and metabolic changes are detected to maintain tissue homeostasis.  
Dysfunctional or unbalanced innate sensing system is closely related to human diseases such as 
cancer (Figure 1). In this study, we discuss in particular the vital intracellular sensors of viral RNA 
or DNA and extracellular sensor on the plasma membrane, with a focus on RIG-I-like receptors 
(RLRs), cyclic GMP-AMP synthase (cGAS), and TLR4 in pathogen defense, cancer inflammation, 
and the cancer immunoediting [4].   
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Figure 1. Innate sensing at the interface of innate immunity and cancer.  
Innate sensing pathways including viral nucleic acids receptor, Toll-like receptor, and 
inflammasome pathways are critical for host protection against pathogen infections. Interplay 
between metabolic changes, microbial metabolites, and cellular degradation machinery shapes 
host innate immunity and inflammation status. Dysregulation of innate sensing and environmental 
immune response leads to chronic inflammation and cancer development.  
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RIG-I-like receptors and cGAS-STING  
DExD/H-box RNA helicases of the RLR family are essential cytoplasmic sensors of RNA 
viruses.  RLR family proteins comprises the retinoic acid-inducible gene-I protein (RIG-I, encoded 
by DDX58), melanoma differentiation-associated protein 5 (MDA5, encoded by IFIH1) and LGP2 
(encoded by DHX58). RLRs harbor a central DExD/H-box helicase domain and a C-terminal 
regulatory domain (RD), which are both required for RNA binding. RIG-I and MDA5 also contain 
two tandem caspase recruitment domains (CARDs) at the N-terminus essential for activation of 
antiviral signaling. Whereas LGP2 does not have the CARD, its intact ATP hydrolysis activity 
exerts a synergetic effect with MDA5 on the effective antiviral response [5].  RIG-I recognizes 5’-
triphosphate capped single-stranded RNA (5’ppp-ssRNA), short double-stranded RNAs (dsRNAs, 
up to 1 kb), such as the polyinosinic-polycytidylic acid (poly (I:C) and dsRNAs containing a 5’-
triphosphate moiety transcribed from AT-rich dsDNA by RNA polymerase III. MDA5 detects 
long dsRNAs (more than 2 kb) [6]. Analyses of Rig-I−/− and Mda5−/− mice have shown that RIG-I 
is essential for the production of type I IFNs in response to various RNA viruses, including 
vesicular stomatitis virus (VSV), Sendai virus (SeV), whereas MDA5 is critical for the detection 
of picornaviridae such as encephalomyocarditis virus (EMCV). Post-translational modifications 
and regulatory host enzymes tightly control signaling transduction mediated by RIG-I and MDA5. 
In uninfected cells, RIG-I and MDA5 are constitutively phosphorylated by protein kinase C at 
serine or threonine residues in their CARDs, thus kept in an inactive state [7]. Besides, RIG-I  is 
held in an auto-inhibitory closed configuration through the interaction of RD with CARD [3]. 
Binding of viral dsRNA releases the CARDs, resulting in a conformational change that permits 
removal of the phosphate groups at S8 and T170 of the RIG-I CARDs and S88 of the MDA5 
CARDs by phosphatase PP1 [8]. Subsequent binding of K63 polyubiquitin (polyUb) chains to 
  4 
RIG-I catalyzed by E3 ubiquitin ligases tripartite motif protein 4 (TRIM4), TRIM25 and Riplet 
(encoded by RNF135) induces tetramerization of RIG-I [9, 10]. A mitochondrial trafficking 
chaperone protein 14-3-3ε in complex with TRIM25 was then recruited for RIG-I translocation to 
mitochondria for interaction with the adaptor protein MAVS. It is still unclear if K63 
ubiquitination mark is necessary for MDA5 signaling since the binding of MDA5 to long dsRNA 
is sufficient to trigger the formation of MDA5 filaments and binding to MAVS. Aggregation of 
MAVS into prion-like filament structures leads to the assembly of a large signaling platform and 
the recruitment of TBK1 and IKK to activate IRF3, IRF7 and NF-κB that leads to the production 
of interferons (IFNs) and proinflammatory cytokines such as TNF and Interleukin-6 (IL-6) [11]. 
Secreted IFNs can bind to IFN receptors through autocrine and paracrine fashions to induce JAK-
STAT signaling and the expression of hundreds of IFN-stimulated genes (ISGs) which target 
critical steps of viral life-cycle as well as for shaping an effective adaptive immune response [12]. 
Cytoplasmic DNA sensor cGAS binds with viral dsDNA and produces the cyclic dinucleotide 
cyclic GMP-AMP (cGAMP) with an unusual 2’-5’ phosphodiester bond. The second messenger 
cGAMP subsequently binds to endoplasmic reticulum (ER)-resident membrane adaptor protein 
STING (encoded by TMEM173), leading to the STING dimerization and K63 ubiquitination 
mediated by TRIM56 [13, 14]. Activated STING translocates from ER to Golgi apparatus and 
perinuclear regions where it interacts with TBK1 and triggers the activation of IRF3 and 
production of type I IFNs [11]. However, cGAS is not stable and either degraded by proteasome 
and autophagy pathways through ubiquitination and desumoylation or cleaved by caspase-1 upon 
inflammasome activation [15-17]. Deubiquitination by TRIM14-USP14 complex and sumoylation 
by TRIM38 ensures the protein stability of cGAS and optimal activation of the cGAS-STING 
pathway [16, 17].  
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Mitochondria as a signaling organelle in the regulation of innate immunity 
Mitochondria as biosynthetic and bioenergetics cellular compartment contribute an active 
metabolic state to provide signaling intermediates during the immune response. Mitochondrial 
reactive oxygen species (mtROS) is critical for PRRs signaling such as nuclear oligomerization 
domain (NOD)-like receptors (NLRs) forming multi-subunit oligomers termed inflammasome. 
Diverse pathogen-associated molecular patterns (PAMPs) and damage-associated molecular 
patterns (DAMPs) including LPS, ATP, K+, and uric acids lead to increase in ROS and lysosomal 
membrane permeabilization, resulting in NEK7-dependent NLRP3 activation, proteolytic 
cleavage and maturation of the pro-inflammatory cytokine IL-1β by activated caspase-1 [18, 19]. 
Following NLRP3 activation, caspase-1 inhibits mitophagy to induce mitochondrial damage [20] 
whereas NF-κB that primes NLRP3-inflammation for activation also prevents the excessive 
inflammasome-induced inflammation via inducing p62/SQSTM1 for Parkin-dependent 
mitophagic clearance [21]. Mitochondrial-associated membrane (MAM) provides a 
mitochondrial/endoplasmic reticulum interface for inter-organelle communication such as the 
regulation of mitochondrial fusion/fission, inflammasome formation and autophagy [22]. It serves 
as a signaling platform for RLR-activated antiviral immunity was evident by the identification of 
the RLR mitochondrial adaptor protein MAVS [23]. Notably, MAVS is also localized on the 
peroxisome membrane. While mitochondrial MAVS induces mainly the IRF3-dependent IFN β, 
peroxisomal MAVS induces IRF1-dependent type III IFN- λ [24]. Besides the antiviral function 
in immune cells, MAVS in the nonhematopoietic origin such as colonic epithelial cells is essential 
for protection against intestinal commensal bacteria and DSS-induced colitis through RIG-I 
detection of bacterial RNA species and production of cytokine IFN-β and antimicrobial peptides 
RegIIIγ [25]. Mitochondria dynamics are also critical for immune cell metabolism and function. 
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While healthy mitochondria display in a fused network promotes, mitochondria fission is 
indicative of damaged mitochondria that inhibits RLR signaling. Under nutrient-restricted 
conditions, mitochondria fuse into large interconnected networks that are essential to sustain 
intramitochondrial fatty acids exchange to maintain mitochondrial respiration and cell survival. 
By contrast, nutrient-rich and cellular damage condition promote mitochondrial fragmentation and 
degradation through mitophagy. Mitochondrial fission is regulated by GTPase dynamin-related 
protein 1 (Drp1) whereas mitochondrial fusion is regulated by mitofusin (Mfn)1 and 2 on the outer 
mitochondrial membrane and optic atrophy protein 1 (Opa1) on the inner mitochondrial membrane 
[26]. It is possible that lipids, metabolites or ROS released from mitochondria during 
mitochondrial morphological changes are necessary for optimal MAVS aggregation and activation 
[27]. MAVS is required for optimal NLRP3 inflammasome activation by mediating the 
recruitment of NLRP3 to mitochondria [28], suggesting the convergence of RLR signaling and 
NLRP3 inflammasome signaling on the mitochondria, although RNA viruses also activate NLRP3 
inflammasome independent of RLR through RIP1 and RIP-3 complex-mediated Drp1 
mitochondrial translocation and phosphorylation at Ser616 to induce aberrant mitochondrial 
fission [29]. Inter-organelle communication by a number of proteins with dual localization 
provides an inter-membrane integration point for innate immune signaling. Nuclear factor 
erythroid 2-related factor 2 (Nrf2) is normal sequestered and localized on the outer mitochondrial 
membrane. It becomes a key transcription factor for redox balance in response to mtROS oxidative 
stress which is also critical for optimal NF-κB activation [30]. Recent studies show that ubiquitin-
binding autophagy receptor p62 is required for induction of hepatocellular carcinomas and 
pancreatic ductal adenocarcinoma through Nrf2 signaling [31, 32], suggesting a link between 
chronic inflammation and oncogenic transformation of epithelial tissues. Therefore, to understand 
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the signaling and metabolic events in the membrane contact sites are important for mounting an 
effective immune response and preventing overwhelming and detrimental cytokine storm.  
TLR4 signaling 
The stimulation of TLR4 by lipopolysaccharide (LPS) induces MyD88-dependent or TIR-
domain-containing adapter-inducing interferon-β (TRIF)-dependent pathways, leading to the 
activation of NF-κB and MAPK or type I IFN signaling, respectively. Of note, intracellular LPS 
also activates caspase-11 non-canonical inflammasome independently of TLR4 [33].  On the other 
hand, NF-κB activation restricts inflammasome activation by eliminating damaged mitochondria 
by PARKIN-induced ubiquitination and p62 selective autophagy degradation [21]. TLR4 initiates 
innate immune responses by activating signaling pathways dependent on the adaptor myeloid 
differentiation primary response gene 88 (MyD88) that is sequentially inducing the activation of 
IL-1 receptor-associated kinase (IRAK) 1 and IRAK4, which in turn recruit the RING-domain E3 
ubiquitin ligase, tumor necrosis factor (TNF)-receptor-associated factor (TRAF) 6. TRAF6-
dependent activation of several MAP3Ks (TAK1, ASK1, MEKK3) in turn activate IKK complex 
or MKKs to activate downstream MAPKs 1) MKK1 and MKK2 activate Erk1/2, 2) MKK3 and 
MKK6 activate p38 3) MKK4 and MKK7 activate JNK [34]. In the TRIF-dependent pathway, 
TRIF interacts with TRAF6 and TRAF3. TRAF6 recruits receptor-interacting serine/threonine-
protein kinase 1 (RIP1), which in turn activates TAK1 complex.  TRAF3, on the other hand, 
recruits TBK1 for IRF3 activation to induce type I IFN genes. Although most cell types share 
general mechanism in the receptor signaling pathway, the manner of signaling transduction and 
amount of cytokine production differ in various types of cells [35].  
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Innate sensing in the immunosurveillance of cancer cells 
The innate immune sensing of tumor-derived DNA and other DAMPs activates the cGAS-
STING pathways in antigen-presenting cells (APCs). The resulted production of type I IFNs, in 
turn, enable and expand a subset of Batf3 or CD103+ dendritic cells (DCs) recruited by tumor-
derived CCL4 [36]. Matured CD103+ DCs are able to transport intact tumor-antigens to tumor-
draining lymph nodes and prime CD8+ T cells, leading to the activation and clonal expansion of 
tumor antigen-specific cytotoxic CD8+ T cells. CD8+ T cells are recruited back to the tumor 
microenvironment under the influence of CXCL9 and CXCL10 and directly contact tumor cells, 
resulting in tumor cell death [37]. In a mouse model of melanoma, CD103+ DCs were required to 
promote anti-PD-L1-mediated anti-tumoral effects when combined with FLT3L and poly (I:C) 
injections [36].  Radiotherapy and chemotherapy induce DNA double-stranded break damage to 
lead to the formation of micronuclei. cGAS is relocalized to the micronuclei and triggers the 
activation of inflammatory gene expression through cGAS-STING pathway [38]. Reports have 
described that T-cell-dependent antitumor response outside of the irradiated field, an abscopal 
effect most often seen in combination with anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) 
immune checkpoint blockade. STING signaling is crucial for the regression of distal tumors in the 
combination of radiotherapy and anti-CTLA4 blockade. These findings suggest a model that cell 
cycle checkpoint inhibition by genotoxic therapies has the beneficial function in conjunction with 
immune checkpoint blockade through activation of local type I IFN production [39]. However, 
deletion of TBK1, the major downstream targets of STING and MAVS, in DCs displays a robust 
antitumor T cells response.  These and other studies suggest that distinct nature of PAMPs, the 
signature of type I IFNs, and subtype of DCs might determine distinct roles in modulating the 
immunostimulatory function of DCs and antitumor T cell response [40-42]. Similarly, high 
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mobility group box 1 (HMGB1), a nuclear non-histone chromatin-binding protein released by 
necrotic cells activates TLR4 signaling but suppresses tumor-associated DCs activation through 
binding to the T-cell immunoglobulin and mucin-domain-containing-3 (TIM-3) [43, 44]. Thus, the 
study of innate immune signaling in pathogen defense might provide mechanistic insights into 
tumor immunity for therapeutic purposes.  
TRIM family proteins in innate immunity and cancer  
TRIM family proteins, most of which contain RING-finger domain and function as E3 
ligase, play various roles in cellular processes including innate immune signaling, autophagy, 
development and carcinogenesis through post-translational modifications [45]. Typically, TRIM 
proteins are characterized by an N-terminal RING-finger domain for its E3 ligase function, one or 
two B boxes and its associated coiled-coil region, C-terminal PRY and SPRY domain (Figure 2). 
TRIM proteins have been shown to modulate protein stability through proteasome or autophagy 
pathways through ubiquitination [45]. Ubiquitin conjugation is catalyzed by the E1 ubiquitin-
activating enzyme, E2 ubiquitin-conjugating enzymes, and E3 ubiquitin ligases. Base on the 
domain structure, E3 ligases have been classified into the homologous to E6-AP COOH terminus 
(HECT) family and the RING-finger-containing protein family. The linkage or conjugation of 
ubiquitin chain through seven internal lysine residues, including K6, K11, K27, K29, K33, K48 
and K63, determines either the proteolytic function ubiquitin chain followed by proteasome- or 
autophagy- degradation, or non-proteolytic functions including protein kinase activation in innate 
immunity, histone regulation, protein translocation and DNA repair [45].  
1) TRIM protein in innate immune signaling: TRIM30α suppresses NF-κB activation by 
promoting TLR-mediated TAB2 and TAB3 degradation [46]. TRIM56 induces K335 mono-
ubiquitination of cGAS and TRIM14 recruits USP14 to cGAS K48 deubiquitination at K414 [17, 
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47]. TRIM25 and TRIM4 synthesize K63 ubiquitin chains of RIG-I at K172 and K164 respectively 
[48-50]. Although previously thought to mediate protection solely in the extracellular 
environment, recent studies have revealed that antibody-mediated protection extends to the 
cytosolic compartment of cells. Viral pathogens coated with antibody isotypes enter the cytosol, 
TRIM21 functioning as an Fc receptor is rapidly recruited and efficient neutralization occurs 
before the virus has had the time to replicate through its Ig binding PRY/SPRY domain [51]. By 
utilizing the antibody-binding activity of TRIM21, a recently developed method was reported for 
the degradation of endogenous proteins [52].  
2) TRIM protein in autophagy: Proteins of TRIM family interact with cargo recognizing 
autophagy adaptor proteins (e.g., p62, NBR1, HDAC6, NIX, NDP52, OPTN), and autophagy core 
regulators ULK1 and Beclin1 to form a protein-recognition/degradation platform. For example, TRIM5α 
interacts with activated ULK1 and Beclin1 and concentrates them in specialized intracellular 
location for autophagy initiation. On the contrary, TRIM17 appears as a negative regulator of 
autophagy by altering the localization of ULK1, suggesting that co-localization of autophagic 
machinery with different TRIM proteins determines the activity of autophagy and localization of 
autophagosome [53, 54]. 
3) TRIM protein in cancer: Upregulation of TRIM59 have been found in gastric tumors 
and glioblastoma through modulating p53 stability and STAT3 activation, respectively [55, 56].  
TRIM24 acts as a tumor suppressor in hepatocellular carcinoma via restricting retinoic acid 
receptor alpha (RARα)-mediating signaling [57]. AMP-activated protein kinase (AMPK) inhibits 
anabolic and facilitates catabolic processes to maintain energy homeostasis, which plays a tumor 
suppressor role in multiple cancers. For example, AMPK inhibits ACC1 and mechanistic target of 
rapamycin (mTOR) to block fatty acid synthesis and promotes autophagy via ULK1.  In cancer, 
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growth-restrictive AMPK pathway is suppressed by cancer/testis antigen melanoma antigen 
(MAGE)-A3/6-TRIM28 complex [58]. TRIM29 lacking the RING-domain, the expression of 
which has an inverse relationship with TWIST1 in breast cancer, feedback inhibits TWIST1-
mediated EMT and invasive phenotype of breast cancer [59].  TRIM29 as a histone-binding protein 
involves in DNA damage responses through phosphorylation of H2AX in response to ionizing 
radiation [60].  
 
Figure 2. Functional domains of the tripartite motif-containing protein family. Adapted and 
reprinted from [49] and [61]. The conserved domains of known human TRIM proteins are 
represented schematically including an E3 ligase RING-finger domain [49], B box and coiled-coil 
domain for protein-protein interaction or self-association [61], and a C-terminal PRY/SPRY 
domain with a unique function in antibody binding.  
 
B cell lymphomas: Intrinsic signaling and tumor microenvironment 
B cell signaling and B cell malignancy 
B cell-intrinsic signaling programs downstream of B cell receptor (BCR), TLR, CD40 and 
cytokine receptors affect B cell function, alternations in signaling lead to the pathogenesis of 
RING B Box Coiled-coil PRY/SPRY
Tripartite motif-containing (TRIM) protein family 
Ig bindingSelf-associationE3 ligase
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autoimmunity and B cell malignancies. For example, enhanced positive signaling or disrupted 
negative signaling downstream of the pre-BCR promotes B cell acute lymphoblastic leukemia. 
Rearrangement of immunoglobulin heavy-chain variable (V), diversity (D) and joining (J) gene 
segments results in the expression of IgM heavy chain paired with non-polymorphic surrogate 
light chains to form pre-BCR at early B cell commitment stage or large pre-B cell stage.  
Chromosomal translocations and gene mutations at this stage give rise to B cell acute 
lymphoblastic leukemia/lymphoma such as BCR-ABL1 translocation, mutations in mixed-lineage 
leukemia (MLL) and pre-B cell leukemia homeobox1 (PBX1). Immature B cells acquire a 
functional BCR and egress from the bone marrow to complete maturation and differentiation into 
follicular B cells, marginal zone B cells and germinal center B cells in spleen or lymph nodes. 
According to different origins of B cell lymphomas in periphery, non-Hodgkin’s B cell lymphomas 
are divided into 1) Circulating and follicular-derived: B cell chronic lymphocytic leukemia (CLL) 
(derives from mature CD5 positive B cells) and Mantle cell lymphoma, 2) Marginal zone-derived: 
splenic marginal zone lymphoma (SMZL) and mucosa-associated lymphoid tissue (MALT) 
lymphoma, and 3) Germinal center-derived: follicular lymphoma, diffuse large B cell lymphoma 
(DLBCL), Burkitt’s lymphoma (BL), and multiple myeloma (plasma cell malignancy). Pre-B cell 
survival and proliferation is driven by IL-7R signaling, which induces the activation of STAT5. 
Pre-BCR signaling activation through CD79A/B activates spleen tyrosine kinase (SYK) and 
Bruton tyrosine kinase (BTK) phosphorylate the B cell linker protein (BLNK). BLNK inhibits the 
AKT activation, thereafter promoting the nuclear translocation of forkhead box protein O1 
(FOXO1). FOXO1 targets the transcriptional repressor B cell lymphoma 6 (BCL6), which inhibits 
cyclin D2 and Myc. BLNK also suppresses STAT5 activation. Increased paracrine and autocrine 
IL-7 stimulation leads to excessive STAT5 activation in pre-B ALL patients. Inactivation 
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mutations in BLNK release the inhibition of AKT resulting in cytoplasmic retention of FOXO1 
and lack of BCL6 expression. Hyperactivation of RAS pathway due to RAS mutations promotes 
ELK1 and cyclic AMP-responsive-element-binding protein (CREB) target genes. Two main 
modes of BCR signaling including tonic signaling, which is activated by PI3K and active signaling 
activates NF-kB by the CARD1-BCL-10-MALT1 complex. Alternations in pre-BCR and BCR 
signaling is closely linked to the pathogenic progression of B cell lymphomas. Thus, the intrinsic 
and tumor environmental stimuli that lead to oncogenic transformation of B cells are needed to be 
studied and reconciled.  
Immune checkpoint in B cell malignancy 
Stimulation of the TCR via major histocompatibility complex (MHC) antigen cross-
presentation by APCs activates T cells. Co-stimulatory receptors and co-inhibitory receptors (or 
immune checkpoint molecules) co-localize with TCR at the immunological synapse where they 
promote or inhibit T cell activation and function [62, 63] (Figure 3). The finding of programmed 
cell-death protein ligand 1/2 (PD-L1/2) is upregulated in lymphoid malignancies whereas CTLA-
4 and PD-1 receptors are highly expressed on tumor-infiltrating lymphocytes (TILs) [64]. The 
activation of CD28 initiates the membrane translocation of CTLA-4 to compete with CD28 for 
engaging with shared ligands CD80 and CD86, thus downregulates the T-cell response. In contrast 
to CTLA-4, PD-1 does not affect co-stimulation, whose expression requires 6-12 h transcriptional 
activation. PD-1 recruits phosphatase SHP-2 and PP2A to directly inhibit TCR signaling. PD-L1 
and PD-L2 are expressed by tumor cells as well as infiltrating leukocytes upon exposure to IFN-γ 
produced by activated T cells or natural killer cells. Immune evasion through the aberrant 
expression of PD-L1 in B cell lymphomas that binds to PD-1 on CD4+ and CD8+ T cells induces 
T cell exhaustion [65, 66]. The clinical trial using anti-PD-1 antibody nivolumab and anti-PD-L1 
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antibody pembrolizumab have durable responses in non-small cell lung cancer and triple negative 
breast cancer. In B cell lymphoma, anti-PD-1 antibody pidilizumab phase I trial showed a response 
in more than 33% of patients including CLL and DLBCL. Studies have been focusing on the 
molecular mechanisms underlying the expression of PD-1/PD-L1 for better immunotherapies. 
Biallelic inactivation of Lkb1 and Pten in lung leads to squamous cell carcinoma (SCC) expressing 
KRT5, p63 and SOX2 associated with infiltrated neutrophils. The SCA1+NGFR+ cell fractions in 
the SCC highly express PD-L1 leading to tumor immune escape [67]. Oncogene MYC was found 
to directly bind to the promoters of two immune checkpoint proteins, CD47 and PD-L1. MYC 
inactivation downregulates CD47 and PD-L1 leading to suppressed tumor growth, which could be 
reversed by ectopic expression of CD47 and PD-L1 [68]. Cyclin-dependent kinase 5 (Cdk5) is 
highly active in medulloblastoma as a critical mediator of IFN-γ-induced PD-L1 upregulation. 
Cdk5 deletion results in persistent expression of IRF2 and IRF2BP2, two transcriptional repressors 
of PD-L1, leading to potent CD4+ T cell-mediated tumor rejection [69]. A recent study in 
commensal bacteria strain Bifidobacterium suggests an emerging role of the microbiome in the 
modulating of antitumor immunity by augmenting dendritic cells and enhancing CD8+ T cell 
priming [70]. Combination therapy by oral administration of Bifidobacterium and anti-PD-L1 
therapy abolishes tumor outgrowth [70]. In a mouse model of chronic inflammation-induced liver 
cancer, accumulation of IgA+ B220- CD138+ B cells with elevated expression of PD-L1 and 
immunosuppressive phenotype that promotes HFD-induced liver cancer. Anti-PD-L1 antibody 
blockade induces liver cancer regression through clonal expansion of liver CD8+ T cells [71]. Thus, 
how to identify the critical immune cell and stromal cell composition that dictates the local and 
systemic tumor microenvironment for tumor cell evasion and metastasis is important for the design 
of combination therapy to treat cancer. 
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Figure 3. The cancer immunity cycle. Reprinted from [64]. A typical antitumor immune 
response involves the following major steps: (1) Tumor antigens are released and captured by 
DCs for processing; (2) DCs present processed antigens to T cells to prime and activate T cell 
receptor (TCR) signaling against tumor-specific antigens in tumor-draining lymph nodes (dLNs). 
T cell antitumor activity is balanced by the coordinated actions of both stimulatory (red-cross) 
and inhibitory (blue-cross) signals. (3) Activated effector T cells travel through blood vessels and 
(4) infiltrate tumor sites by crossing the endothelial barrier. (5) Tumor-infiltrating T cells (TILs) 
recognize cancer cells through the interaction between TCR and cognate antigens bound to 
MHC-I on tumor cells. Engineered therapeutic T cells expressing chimeric antigen receptor 
(CAR-T) are also used in the clinic to boost tumor killing. Immunomodulatory monoclonal 
antibodies can overcome local immunosuppression by blocking suppressive PD-1receptors and 
(6) eventually initiate the tumor cell killing machinery.  
 
Multi-faceted roles of MDSCs in the tumor immunosuppression  
MDSCs are one of the major components with potent immunosuppressive activity in tumor 
microenvironment through remodeling the tumor microenvironment and establishing pre-
metastatic niche [72, 73]: 1) production of T cell suppressive cytokines arginase (Arg1), inducible 
NOS (iNos), reactive oxygen species (ROS); 2) suppressing T cell activity via deprivation of L-
cysteine and L-arginine 3) TGF-β, IL-10 to induce regulatory T cells (Tregs). MDSCs are broadly 
defined as CD11b+ myeloid cells, including Ly6G+Ly6Clo polymorphonuclear (PMN)-MDSCs 
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(similar to neutrophils) and Ly6G-Ly6Chi monocytic (M)-MDSCs. For example, accumulation of 
a subset of MDSCs, CD14+HLA-DRlo M-MDSCs, in CLL patients has the capacity to inhibit T 
cells activation and induce Treg by indoleamine 2,3-dioxygenase (IDO) [74]. The increase of 
CD66b+CD33lo HLA-DR- PMN-MDSCs in peripheral blood was found with Arg1 activity in a 
cohort of 31 indolent lymphomas [75]. MDSCs has been recently shown to diminish the efficacy 
of immune checkpoint blockade.  Anti-CTLA4 or anti-PD1/PD-L1 antibody checkpoint blockade 
generates a durable therapeutic response in a variety of cancer types but not prostate cancer. One 
of the mechanisms underlying patient resistance to immune checkpoint blockade is the 
observations of PMN-MDSCs accumulation in a prostate carcinoma mouse model and patients 
with metastatic castration-resistant prostate cancer [76, 77]. Specifically, Hippo-YAP signaling 
induces CXCL5 secretion by prostate cancer cells to attract CXCR2-expressing MDSCs. Cocktail 
inhibitors targeting MDSCs infiltration frequency and immunosuppressive activity (SX-682, 
Cabozantinib, BEZ235, PI-3065, GSK2636771) can synergize with immune checkpoint blockade 
to invigorate anti-tumor T cell response [76, 77]. Similarly, macrophage-derived TNF-α induces 
expression of COP9 signalosome 5 (CSN5) in tumor cells leading to the deubiquitination and 
stabilization of immune checkpoint molecule PD-L1. CSN5 inhibition by curcumin sensitizes 
tumor cells to anti-CTLA combinational therapies [78]. Interestingly, tumor-associated 
macrophages express PD-1 and M2-like surface profile. Blockade of PD-1/PD-L1 in vivo 
promotes macrophage phagocytosis and reduces tumor growth [79], suggesting that the immune 
checkpoint blockade therapy may also have a direct effect on the M2 subtype of tumor-associated 
macrophages. 
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Autophagy: Inflammation and Cancer 
Autophagosome biogenesis and non-canonical autophagy 
Autophagy, or macroautophagy, is a cellular homeostatic machinery involved in the 
disposal of the damaged organelle, invaded pathogens and denatured proteins through lysosomal 
degradation pathway, which have been intensively studied in the past decade [80, 81]. Under 
glucose starvation, AMPK promotes autophagy through phosphorylation of ULK1 at Ser317 and 
Ser777, a component of the autophagy initiation ULK1 complex 
(ULK1/ATG13/FIP200/ATG101) [82]. In resting state or nutrient abundant, the mTOR represses 
autophagy through phosphorylation of ULK1 at Ser757 thus disrupting the ULK1-AMPK 
interaction [82]. During nucleation stage, AMPK activates the PI3KC3 VPS34 complex 
(VPS34/Beclin1/VPS15/ATG14L) by phosphorylating S91/S94 in Beclin1 upon glucose 
withdrawal [83], while ULK1 phosphorylates Beclin1 at Ser14  [84] and enhances the activity of 
class III PI3K complex upon amino acid withdrawal. Of note, ULK1 is required only for short-
term starvation where the VPS34 complex is needed for both long- and short-term starvation-
induced autophagy [83]. In expansion stage, the ATG12-ATG5-ATG16L complex is recruited by 
phosphatidylinositol-3-phosphate (Ptdlns3P)-binding protein WIPI2 to the autophagosome 
precursor structure. The ATG16L1 complex is generated through ubiquitin-like conjugation 
reaction, in which ATG12 is conjugated to ATG5 by ATG7 and ATG10. ATG16L1 then non-
covalently binds the ATG5-ATG12 conjugate to form a multimeric complex. In parallel, 
microtubule-associated protein 1 light chain 3 (LC3) is processed by the protease ATG4 and 
subjected to a second ubiquitin-like conjugation reaction via ATG7 and ATG3. ATG16L1 
complex facilitates the lipidation of LC3 with phosphatidylethanolamine (PE) to form LC3-II [85]. 
LC3-II is recruited to autophagosomal membranes and is required for the fusion with lysosome-
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mediated by class C vacuolar protein sorting (VPS) and SNARE-like proteins for both non-
selective and selective autophagy-mediated degradation [86-88]. Subsets of canonical autophagy 
pathway have been observed to function independently of other components of the autophagy 
machinery. 1) LC3-associated phagocytosis (LAP): LAP mediates the maturation of phagosomes 
independently of the ULK1 complex but requires the NOX2, Rubicon, PI3KC3 complex and 
ATG16L1 complex [89]. 2) Brucella abortus-containing vacuole formation: Brucella abortus 
subverts the ULK1 and PI3KC3 complexes but not ATG16L1 or LC3 to generate pathogen-
containing vacuoles [90]. 3)Toxoplasma gondii vacuole formation: Recruitment of immunity-
related GTPase (IRGs) and guanylate-binding proteins (GBPs) to parasitophorous vacuole during 
Toxoplasma gondii or norovirus infections requires ATG16L1 complex but not autophagosome 
formation or lysosomes [91, 92]. Other examples such as ATG5 prevents neutrophil-inflammation 
during Mycobacterium tuberculosis infection independently of other components in ATG16L1 
complex [93]. ATG9L1 represses STING pathway independently of LC3 conjugation [94].  
Autophagy in inflammation and cancer 
While studies had focused on the cell-autonomous nature of autophagy, it emerges that the 
autophagy-mediated tumor suppression is executed through suppression of chronic tumor-
promoting inflammation and promotion of anti-tumor immunity [81, 95]. Autophagy in pre-
malignant cells restrains their ability to establish chronic inflammation, by contributing to the 
elimination of damaged mitochondria and redox-active protein aggregates, interactions with 
inflammatory signaling molecules to limit the release of ROS, mtDNA and micronuclei to quench 
pro-inflammatory cytokines. For example, recruitment of ATG16L1 complex by NLRX1 and Tu 
translation elongation factor, mitochondrial (TUFM) to mitochondria promotes mitophagy leading 
to the removal of mitochondrial MAVS and suppressed type I IFN signaling [96]. Beclin1 binding 
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to cGAS induces autophagy to neutralize cytosolic DNA and inhibits cGAS-mediated type I IFN 
signaling [97]. cGAS generates cyclic dinucleotides that activate ULK1 leading to an inhibitory 
phosphorylation of STING [98]. In adipose tissue, a unique role of TBK1 in mediating the 
bidirectional crosstalk between inflammatory signaling pathway and energy sensing. The high-fat 
diet-induced TBK1 expression to repress AMPK to inhibit respiration and increase energy storage. 
On the other hand, TBK1 phosphorylates and induces IKK kinase NIK degradation, thus 
attenuating NF-κB activity. Activation of AMPK promotes catabolic processes and increase TBK1 
activity through ULK1. Adipocyte-specific deletion of TBK1 increases energy consumption and 
inflammation-induced glucose tolerance [99]. p62 deficiency impairs the lysosomal localization 
and activation of mTORC1 in response to amino acids and Tuberous sclerosis complex 1 (Tsc1) 
deficiency. p63-MEKK3 complex activates MKK3/6 and subsequent activation of p38δ, which in 
turn feedback phosphorylates p62 and recruits TRAF6 for mTORC1 K63 ubiquitination and 
activation and expression of Myc. P62 levels differ in cancer cells and tumor microenvironmental 
stroma counterpart. While p62 high in cancer cells, induces NRF2 and mTORC1 signaling to 
suppress tissue oxidative toxicity to promote cancer cell growth, p62 low in stromal fibroblasts 
exhibits increased production of IL-6 that promotes TGF-β synthesis and formation of cancer-
associated fibroblasts (CAF) [100, 101].  
Intact autophagic responses in pre-malignant cells provide safeguard to the genetic 
homeostasis of healthy tissues. Beclin1 promotes tumorigenesis as evident by the spontaneous 
tumor formation in the mice with single-copy loss of beclin1. The similar phenotype can also be 
observed in mice ablated with the Beclin1-interacting proteins, Ambra1[102] and Bif-1[103]. Yet, 
how tumor regulates autophagy and whether autophagy affects tumor growth is controversial in a 
context-dependent manner [104, 105]. Post-translational modifications of Beclin1 may have roles 
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in determining the inducible or inhibitory function in autophagy-dependent and autophagy-
independent responses. Study of Beclin1 acetylation status controlled by p300 and SIRT1 at K430 
and K437 fine-tunes the autophagy induction and xenograft tumor growth. Mutant with both K430 
and K437 substituted to arginines enhances autophagosome maturation and tumor growth 
suppression, suggesting acetylation of Beclin1 suppresses its function in autophagy induction 
[106]. Akt-mediated phosphorylation of Beclin 1 enhanced its interactions with 14-3-3 and 
vimentin intermediate filament proteins, and vimentin depletion increased autophagy and inhibited 
Akt-driven transformation. Thus, Akt-mediated phosphorylation of Beclin1 functions in 
autophagy inhibition, and the formation of an autophagy-inhibitory Beclin 1/14-3-3/vimentin 
intermediate filament complex to promote cancer growth. Expression of a Beclin1 mutant resistant 
to Akt-mediated phosphorylation increased autophagy, reduced anchorage-independent growth, 
and inhibited Akt-driven tumorigenesis [107]. Similarly, EGFR mediates Beclin1 phosphorylation 
in autophagy inhibition and tumor chemoresistance [108]. USP10 mediates the deubiquitination 
of tumor suppressor p53, mutual stabilization between deubiquitinase (USP10 and USP13) and 
Beclin1 provides a mechanism for Beclin1 to control the levels of p53 [109]. Small molecular 
specific and potent of autophagy inhibitor (spautin-1) targets USP10 and USP13, leading to 
suppression of Beclin1 and p53. Autophagy is a pro-survival mechanism in cancer cells in response 
to stress and starvation, inhibition of autophagy by spautin-1 may sensitize tumor cells to apoptosis 
under therapeutic stress.  The mutual exclusion was found between Beclin1 and anti-apoptotic 
protein Mcl-1 by competing for a common deubiquitinase USP9X in an autophagy-independent 
manner. In a model of melanoma, Beclin1 restrains tumorigenesis by promoting Mcl-1 degradation 
[110]. Oncogenic H-Ras induces the expression of BH3-only protein Noxa, which displaces the 
Mcl-1 from Beclin1 thereby stabilizes Beclin1. Ablation of Noxa or Beclin1 attenuated Ras-
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induced cell death, suggesting a mechanism that mediates caspase-independent but autophagy-
dependent cell death by Ras [111]. Thus, the impact of Beclin1 on malignant transformation is 
complex and may involve processes independent of autophagy and cell-type specific role of 
autophagy, such as that of microenvironmental autophagy [112]. 
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CHAPTER II  
ASSEMBLY OF THE WHIP-TRIM14-PPP6C MITOCHONDRIAL COMPLEX 
PROMOTES RIG-I-MEDIATED ANTIVIRAL SIGNALING* 
 
Introduction 
Retinoic acid-inducible gene-I (RIG-I), as a major cytosolic sensor of viral double-stranded 
RNAs (dsRNAs), initiates an anti-viral immune response. In uninfected cells, RIG-I is kept in an 
inactive state by 1) an auto-inhibitory closed configuration through the interaction of C-terminal 
repressor domain with N-terminal caspase activation and recruitment domains (CARDs) [3] and 
2) the constitutive phosphorylation of its CARD by protein kinase C [7]. Binding of viral dsRNA 
releases the CARDs, resulting in a conformational change that permits removal of the phosphate 
groups at S8 and T170 of the RIG-I CARDs by phosphatase PP1 [8]. Subsequent binding of K63 
polyubiquitin (polyUb) chains to RIG-I induces oligomerization and translocation to mitochondria 
for interaction with MAVS, resulting in recruitment of kinases TBK1 and IKK ε to activate IRF3 
that leads to the production of type I interferons (IFN-I) [9, 11]. Given the importance of RIG-I 
pathway in the antiviral immune response, the mechanisms that regulate RIG-I activation and 
mitochondrial translocation remain a topic of intense research. For example, K63 ubiquitination 
of RIG-I on lysine (K) 172 by TRIM25 was shown to be necessary for RIG-I mitochondrial 
targeting by chaperone protein 14-3-3ε [113]. However, K172R mutant is unable to entirely block 
the RIG-I activation induced by Sendai virus [114], suggesting the possibility of an alternative 
                                               
*  This chapter is reprinted and reused from “Assembly of the WHIP-TRIM14-PPP6C Mitochondrial 
Complex Promotes RIG-I-Mediated Antiviral Signaling”. Peng Tan, Lian He, Jun Cui, Chen Qian, Xin Cao, 
Meng Lin, Qingyuan Zhu, Yinyin Li, Changsheng Xing, Xiao Yu, Helen Y. Wang, Rong-Fu Wang, 2017. 
Molecular Cell. 68(2):293-307. Copyright 2017 by Elsevier.  
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“ubiquitin-message” initiating RIG-I activation and signaling transduction. Recent studies have 
highlighted the importance of mitochondria as a central signaling platform, which participates in 
a broad range of innate immune pathways. For example, the adaptor MAVS associates NLRP3 on 
the mitochondrial membrane for inflammasome activation [115]. Yet, the temporal and spatial 
organization of the protein complex that builds a mitochondrial antiviral signalosome for RIG-I 
signaling transduction is still poorly defined. The recent study of RIG-I phosphorylation revealed 
a negative feedback mechanism by death-associated protein kinase 1 (DAPK1) [116]. Besides 
PP1, any phosphatase involved in the feedback regulation of RIG-I dephosphorylation is still 
elusive.  
WHIP functions to promote RAD15 stabilization on ssDNA to maintain genomic stability 
at stalled replication forks through its ATPase activity [117]. In addition, WHIP contains an 
ubiquitin-binding zinc-finger domain (UBD) shown to bind polyUb chains during DNA repair 
[118]. However, the cytosolic function of this protein and its involvement, if any, in RLR-mediated 
IFN-I activation is mostly unclear. Recent studies also have identified PPP6C as a phosphatase for 
Aurora A for mitosis regulation and a key driver for skin basal cell carcinoma [119, 120]. Yet, the 
function of PPP6C in regulating IFN-I production has not been studied. By coupling IFN-
stimulated response element (ISRE) reporter luciferase assay-based shRNA screening of TRIM 
family genes with yeast-two hybrid screening, we uncovered a more complex model of RIG-I 
activation than previously appreciated in that a feedback regulation of RIG-I activation and 
mitochondrial translocation by a mitochondrial membrane-associated complex containing 
TRIM14, WHIP, and PPP6C.  
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Methods and Materials 
Cells and viruses  
Human embryonic kidney (HEK) 293T (referred to as 293T cells), THP-1, and Vero cells 
were maintained in Dulbecco’s modified Eagle medium (DMEM, ThermoFisher) supplemented 
with 10% fetal calf serum (Sigma Aldrich), 100 µg/ml penicillin, 100 µg/ml streptomycin (Sigma 
Aldrich) and non-essential amino acids (ThermoFisher). For stable expression of FLAG-RIG-I in 
293T cells, entry clone of RIG-I (pENTR221-RIG-I) was subcloned into PFUWIG-CMV-FLAG-
IRES-GFP-B vector for lentivirus packaging and subsequent 293T cells transduction. Cells were 
maintained in a humidified incubator with 5% CO2 at 37°C. To detect TRIM14 mRNA expression 
in human PBMC, T cells or B cells, buffy coats from healthy blood donors (obtained by the Gulf 
Coast Regional Blood Center, Houston, TX) were used for isolation of PBMCs by density-gradient 
centrifugation with Lymphoprep (Nycomed Pharm). The isolation and handling of PBMCs were 
done in accordance with institutional guidelines and protocols approved by Houston Methodist 
Research Institute. Human T cells and B cells were isolated from PBMC using DynabeadsTM 
Untouched Human T cells and B cells kit (ThermoFisher). EMCV, VSV (American Type Culture 
Collection) were amplified in Vero and 293T cells, respectively, and stored at -80oC until used.  
Cloning and plasmids  
Expression constructs TRIM14, RIG-I, MDA5, LGP2 and MAVS, WHIP, PPP6C, 
PPP6R1, PPP6R2, and PPP6R3 were either generated from Entry clone library or were cloned 
from cells by RT-PCR using the gateway cloning system (ThermoFisher). Final constructs 
contained an affinity tag (FLAG, HA, Myc, or GFP) and were transcribed under the control of the 
CMV promoter. Deletion or truncation of TRIM14 (NT, 1-265), TRIM14 (CT, 266-442), WHIP 
(UBD, 1-245), WHIP (AAA+ATPase containing domain, 246-665) were generated from entry 
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clone by PCR and subcloned into final constructs containing affinity tag. Point mutations, 
including FLAG-RIG-I (K99), FLAG-RIG-I (K164R), FLAG-RIG-I (K169), FLAG-RIG-I 
(K172R), FLAG-RIG-I (K788R), HA/Myc-WHIP (D37A), HA/Myc-WHIP (T294A) HA-PPP6C 
(R85A), HA-PPP6C (H114Y), HA-PPP6C (K132N), HA-PPP6C (P186S), HA-PPP6C (R264C) 
were generated by using the QuickChange Lightning Multi Site-Directed Mutagenesis Kit 
(Agilent) as previously described [121].  
Immunofluorescence assay and confocal microscopy 
The immunofluorescence assays and confocal microscopy were conducted as described 
previously [122]. WT, WHIP KO, MAVS KO, or TRIM14 KO 293T cells grown on glass-bottom 
dish (MatTek) in complete medium were co-transfected with fluorescently tagged expression 
vectors for RIG-I (DsRed2, GFP, or mCherry), TRIM14 (mCherry, or GFP), WHIP (tagBFP, or 
GFP), PPP6C (mCherry or GFP) or affinity tagged expression vectors for HA-WHIP, HA-PPP6C, 
HA-TRIM14 for 24 h. Cells were either left untreated or treated with poly(I:C)-LMW for 6 h. 
Cells were then fixed in 4% paraformaldehyde solution in PBS at room temperature for 15 min 
and permeabilized at room temperature with 0.1% Triton X-100/PBS. Subsequently, cells 
transfected with HA-WHIP, HA-PPP6C or HA-TRIM14 were incubated with anti-HA antibody 
in PBS containing 2% BSA for 16 h at 4°C. Specific antibodies for detecting endogenous TRIM14, 
RIG-I, MAVS, WHIP, and PPP6C were used in 1:200 dilution. Cells were then washed three times 
with PBS and incubated with secondary fluorescent antibody for 1 h. The nucleus was then labeled 
with DAPI for 5 min in the dark and then followed by three washes in PBS. Mitochondria were 
labeled with Deep Red (abs/em ~644/665 nm) Mitotracker fluorescent dye. ER was labeled with 
mCherry-sec61β. Samples were then visualized using Nikon Eclipse Ti-E microscope. All 
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acquired images were analyzed and the correlation coefficient (r) of pixel intensity values was 
extracted by using the Nikon NIS-Elements AR package or the ImageJ (NIH) software. 
Protein fractionation by size-exclusion column  
Size-exclusion chromatography was conducted as previously described [121]. Briefly, WT, 
MAVS KO and TRIM14 KO THP-1 cells (5 × 107) were mock treated or infected with VSV for 12 
h. Cells were lysed with low salt lysis buffer (50 mM Tris, pH7.5; 150 mM NaCl; 1% Triton-X; 5 
mM EDTA; 10% (v/v) glycerol with protease inhibitor cocktail [Roche]) and then were 
centrifuged at 20,000 rpm for 20 min at 4°C. 10-100 µM protein samples were loaded onto a size-
exclusion column (Superose 6 10/300 GL) with the capacity to separate the large protein 
complexes. Samples were fractionated in a buffer consisting of 20 mM Tris−HCl pH 7.3, 150 mM 
NaCl, 2 mM dithiothreitol and 0.6% N-lauroylsarcosine at a flow rate of 0.5 ml min−1 and 
collected as 0.5 ml fractions after passage through the void volume. SDS-PAGE separated protein 
fractions and detected by immunoblot with antibodies against WHIP, TRIM14, and PPP6C. 
Immunoprecipitation and immunoblot analysis  
For immunoprecipitation experiments, whole cell extracts obtained 24 h post-transfection 
or via ligand stimulation were lysed in low salt lysis buffer (50 mM Tris, pH7.5; 150 mM NaCl; 
1% Triton-X; 5 mM EDTA; 10% (v/v) glycerol with protease inhibitor cocktail [Roche]) or RIPA 
buffer (150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM 
Tris, pH 8.0 protease inhibitor cocktail [Roche]) and shook on ice for 15 min. Whole cell lysates 
were incubated for 4 h at 4°C with the indicated antibodies and protein A/G beads (Pierce), or 
NeutrAvidin-beads for biotin-poly(I:C)-LMW pull-down or with anti-FLAG or anti-HA agarose 
gels for FLAG-tagged protein pull-down (Sigma). After incubation, beads were washed 5 times 
with 1 ml low salt lysis buffer or RIPA buffer, boiled with 4x SDS loading buffer, and subjected 
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to SDS-PAGE (Bio-Rad). Proteins were transferred to nitrocellulose membranes (Bio-Rad). 
Membranes were blocked in 5% dry milk/TBST for 1 h and incubated with using anti-HA, anti-
Myc, anti-FLAG, RIG-I, MAVS, p-IRF3, IRF3, TRIM14, WHIP, PPP6C, phosphor-RIG-I (pS8 
or pT170), or β-actin. Immunoblots were developed using the Luminata™ Western HRP 
Chemiluminescence Substrates (Millipore) and ChemiDoc™ XRS+ System with Image Lab (Bio-
rad). 
Luciferase reporter assay 
293T (2 x 105) cells were seeded into 24-well plates the day before transfection. Cells were 
co-transfected with the IFN-β or ISRE promoter luciferase reporter and Renilla luciferase internal 
control (pRL-TK) using Lipofectamine 2000 (Invitrogen). Scrambled (control) shRNA and 
shRNA plasmids for TRIM family proteins (ThermoScientific) were utilized for ISRE reporter 
luciferase assay screening. Cells were stimulated with 2 µg RIG-I or MDA5 ligand poly(I:C)-
LMW or poly(I:C)-HMW 24 h post-transfection. Empty pcDNA-HA/FLAG/Myc vector was used 
to ensure equal amounts of DNA among the wells. Luciferase activity was determined using the 
Dual-Luciferase Assay (Promega) with the Luminoskan Ascent Luminometer (Thermo Scientific) 
as previously described [123]. Reporter gene activity was normalized to the internal control.  
Cytokine-release assay 
Human IFN-β was detected using an ELISA kit (PBL Biomedical Laboratories) as 
previously described [124]. Briefly, diluted supernatants and human IFN-β standards were applied 
to the pre-coated 96-well plate and incubated for 2 h at room temperature. The plate was then 
washed and incubated with biotin-conjugated detection antibody (1:1000) for 1 h at room 
temperature. Next, the plate was washed and incubated with HRP conjugate concentrate for 
30 min. The plate was washed and incubated with the tetramethylbenzidine (TMB) substrate 
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solution (Sigma-Aldrich). The reaction was stopped with 2 M H2SO4. The absorbance of each well 
was recorded at 450 nm. The absorbance of the standard sample was used to construct the standard 
curve. 
Quantitative RT-PCR analysis  
Total RNA was isolated from cells or tissues, and the first-strand cDNA was generated 
from total RNA using oligo-dT primers and reverse transcriptase II (Invitrogen). Quantitative RT-
PCR (qRT-PCR) was performed using specific primers and the ABI Prism 7000 analyzer (Applied 
Biosystems) with SYBR® GreenER™ qPCR SuperMix Universal (Thermofisher). Target gene 
expression values were normalized to hGAPDH.  
Construction of sgRNA/Cas9 LentiCRISPR and viral transduction 
We designed human TRIM14, WHIP, and PPP6C sgRNAs using an online CRISPR design 
tool (crispr.mit.edu) by inputting targeted exon sequence. Four hTRIM14 sgRNAs were designed 
and cloned into the BsmB1 site of lentiCRISPR vector containing Cas9-P2A-puromycin and were 
verified by sequencing analysis. The sgRNA-containing plasmids were transfected into 293 cells 
with pCMV-VSV-G plasmids and p∆8.9. After two days, the virus-containing medium was 
subjected to ultracentrifugation (20,000 x g at 4°C for 2 h) and frozen at -80°C. 293 or THP-1 cells 
were transduced with control sgRNA or TRIM14-, WHIP-, or PPP6C-sgRNA-containing 
lentiCRISPR viruses. Transduced cells were selected in the presence of puromycin (Invivogen) 
for 48 h and subjected to ligand stimulation or viral infection. 
Proteomic Mapping of TRIM14 Vesicle-like Puncta in HEK293 Cells 
In situ biotin labeling of proteins located <20 nM of the TRIM14–APEX2 fusion protein 
was performed as previously described (Jing et al., 2015). A detailed protocol can be found at 
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Nature Protocol Exchange (http://www.nature.com/protocolexchange/protocols/4109). Briefly, 
the full-length of TRIM14 was cloned using primers EGFP-TRIM14-APEX2 forward 50-
CGGCTTAAGATGGCGGGCGCGGCGACCGGG-30 and EGFP-TRIM14-APEX2 reverse 50- 
GAAGATCTGCGGGGCAGCCGGGGGATGC TGAT-30 to replace Connexin43 in pcDNA3 
Connexin43-GFP-APEX2 (Addgene# 49385). HEK293 cells transfected with EGFP-TRIM14-
APEX2 were externally treated with 500 mM Biotin-Phenol for 30 min at 37 ℃ and then treated 
with 3 mM freshly prepared H2O2 for exactly 1 min at room temperature. After 1 min of labeling, 
cells were washed three times with quencher solution (10 mM sodium azide, 10 mM sodium 
ascorbate, and 5 mM Trolox). Cells were then either subjected to immunofluorescent staining (IF) 
with Streptavidin DyLight 594 or lysed with 1X RIPA buffer for immunoprecipitation and mass 
spectrometry analysis. 
Yeast two-hybrid screening 
Yeast two-hybrid screening was carried out with the Matchmaker GAL4 Two-hybrid 
System 3 using the AH109 yeast strain. To construct a bait plasmid, full-length TRIM14 was 
cloned in-frame into the GAL4 DNA-binding domain of pGBKT7 (pGBKT7-TRIM14-BD). A 
human universal Matchmaker cDNA library (pGADT7-AD Mate & PlateTM library) was used to 
screen ~1 × 106 clones. Transformed and mated cells were grown on –Leu, –Trp medium. TRIM14 
interaction with WHIP or PPP6C was verified on high stringency plates (–Leu, –Trp, –His, –Ade) 
and with a β-galactosidase filter assay and Aureobasidin A (AbA) resistance in serial dilution (10-
fold each).  
Surveyor nuclease assay for genome modification 
293T cells were transduced with control or TRIM14-sgRNA, WHIP-sgRNA, PPP6C-
sgRNA, RIG-I-sgRNA and MAVS-sgRNA LentiCRISPR contructs. The transduced cells 
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underwent puromycin selection for 2 days (2 µg/ml). Genomic DNA was extracted using the 
Quick-gDNA Kit (Zymol Research) according to the manufacturer’s protocol. The genomic region 
flanking the two CRISPR target sites was PCR amplified for sequencing: h-TRIM14 sgRNA-3 
forward 5’-GGACTACAGGTGCATGCC-3’, h-TRIM14 sgRNA-3 reverse 5’-
CATTGGCTCCATATTGGG-3’; h-TRIM14 sgRNA-4 forward 5’-
GTATATGCAATCCTCCTC-3’, h-TRIM14 sgRNA-4 reverse 5’-
CGGCCATGGTGGACACGG-3’; h-WHIP sgRNA-1/2 forward 5’-
CCGGGGCAAACGGCCACGAAC-3’, h-WHIP sgRNA-1/2 reverse 5’- 
GGCGCGTCGTAGCTCTCGCGG-3’; h-PPP6C sgRNA-1/2 forward 5’-
GCCGAGCCTTCTAAATAAAG-3’, h-PPP6C sgRNA-1/2 reverse 5’- 
CCAGCAGGTTTCGCGGGGTG-3’; h-RIG-I sgRNA forward 5’-
GCACTTTGTGCTCAGTCACTG-3’; h-RIG-I sgRNA reverse 5’- 
GGCTTCCTCGGTGCGGAGGG-3’; h-MAVS sgRNA forward 5’-
GTAATCCCCAAACTTGGGAGG-3’; h-MAVS sgRNA reverse 5’- 
CTGAGGCAGGAGAATCACTTG-3’. The PCR products were purified using the Gel DNA 
Recovery Kit (Zymol Research) according to the manufacturer’s instructions. Purified PCR 
products from control and test cells were mixed and subjected to a reannealing process to produce 
heteroduplex formation according to the SURVEYOR Mutation Detection Kit (Transgenomic) 
protocol. After reannealing, products were treated with SURVEYOR nuclease and enhancer S 
(Transgenomic). The digested products were then subjected to electrophoresis on a 2% agarose 
gel with SYBR gold stain. 
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Statistical analysis  
Descriptive statistics, including means, standard deviations, medians, and ranges, were 
computed for each group and analyzed with the Student’s t-test or, for multiple comparisons, with 
ANOVA. Data are presented as the mean ± standard error. All analyses were performed with 
GraphPad Prism 6 (GraphPad Software, La Jolla, CA). P-values < 0.05 were considered 
significant. 
Results 
TRIM14 positively regulates RIG-I-mediated IFN-I signaling  
To systematically analyze human TRIM proteins for their regulatory roles in efficient 
initiation and signaling of innate immunity, we performed a functional screening using pooled 
shRNAs (3 shRNAs per gene) targeting 42 TRIM family proteins in 293T cells. Among them, we 
identified TRIM14 as a potent positive regulator of poly(I:C)-LMW induced ISRE-Luciferase 
(Luc) reporter activity and RIG-I-mediated IFN-I signaling (Figure 4A).  
To further define the positive role of TRIM14, we determined the status of IRF3 
phosphorylation (p-IRF3) in CRISPR/Cas9-mediated TRIM14 depleted 293T following 
stimulation with RIG-I receptor ligands such as intracellular poly(I:C)-LMW or VSV at various 
time points. TRIM14 KO 293T and THP-1 cell clones using TRIM14 sgRNA-4 were generated 
for subsequent experiments. Notably, the extent of p-IRF3 was markedly diminished in TRIM14 
KO 293T cells after poly(I:C)-LMW stimulation or VSV infection (Figures 4B and 4C). 
Consistently, TRIM14 deficiency dramatically increased GFP-positive VSV replication during 24 
h infection (Figures 4D and 4E).  
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Figure 4. TRIM14 positively regulates RIG-I signaling. (A) ISRE promoter luciferase assay of 
293T cells transfected with control shRNA (shControl) or shRNAs (3 shRNAs per gene) targeting 
42 TRIMs followed by stimulation with intracellular low-molecular-weight poly(I:C) ((I:C)-
LMW) (5 µg/mL). Results are expressed relative to Renilla luciferase activity. Red dashed line 
indicates the average normal control shRNA activity. TRIM25 (positive control) and TRIM14 are 
highlighted in red.  (B and C) IB analysis of WT and TRIM14-deficient (KO; TRIM14 sgRNA-4) 
293T cells treated with poly(I:C)-LMW (B) or infected with VSV (C) for the indicated time points. 
(D and E) Fluorescence microscopy and phase-contrast of WT and TRIM14 KO 293T cells infected 
with VSV-eGFP (MOI=0.05) at the indicated time points (D). Images of living cells were captured 
to compare the degree of virus replication (GFP field, top) and virus cytopathic effect (bright field, 
below). Scale bars: 10 µm. Viral replication kinetics was indicated by the percentage of GFP+ cells 
at the indicated time points (E). (F) IB analysis of WT and TRIM14 KO (TRIM14 sgRNA-4) THP-
1 cells infected with EMCV, VSV, SeV, or HSV-1 for 10 h. The diagram shows ligand-specific 
activation of antiviral IFN-I signaling pathways, including cGAS-STING by HSV-1, MDA5 by 
EMCV, and RIG-I by VSV and SeV (F, right). (G and H) ELISA of IFN-β production (G) and 
qPCR analysis of virus RNA (H) in WT and TRIM14 KO THP-1 cells mock treated or infected 
with EMCV, VSV, SeV, or HSV-1 for 12 h. (I and J) IFN-β promoter luciferase assay (I) and IFN-
β mRNA expression (J) in 293T cells co-expressing TRIM14 along with RIG-I, MDA5, MAVS, 
TBK1, or IRF3. (K) Co-IP and IB analysis of 293T cells co-transfected with Myc-TRIM14 and 
FLAG-RIG-I, MAVS, MDA5, or LGP2, followed by stimulation (VSV for RIG-I and MAVS; 
EMCV for MDA5 and LGP2) for 8 h. WCL, immunoblot analysis of whole-cell lysates without 
immunoprecipitation. Data in (A), (E), (G-J) are expressed as means ± SD of three independent 
experiments. *p<0.05, **p<0.01, NS: not significant, versus controls. 
 
We next determined whether knockout of TRIM14 would inhibit IFN-I activation under 
physiological conditions. We treated WT and TRIM14 KO THP-1 cells with various viruses 
targeting different DNA or RNA sensors, including VSV and Sendai virus (SeV) for RIG-I, EMCV 
for Melanoma Differentiation-Associated protein 5 (MDA5), and HSV-1 for Cyclic GMP-AMP 
synthase (cGAS) as shown in the diagram (Figure 4F, right). We found that TRIM14 deficiency 
in THP-1 cells markedly dampened p-IRF3, IFN-β secretion, and increased virus replication after 
infection with either RNA viruses (VSV and SeV), or DNA virus (HSV-1) (Figures 4F-H). By 
contrast, EMCV-induced p-IRF3 was only slightly reduced, but no changes in IFN-β expression 
and viral replication, suggesting a dominant role of TRIM14 in the RIG-I pathway. Effect of 
TRIM14 on cGAS was similar to our recent report, showing that TRIM14 regulates cGAS stability 
[17]. As TRIM14 enhances activation of RIG-I signaling, we next sought to determine the 
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molecular mechanisms of how TRIM14 regulates RIG-I signaling. We found that TRIM14 
significantly promoted RIG-I- and MAVS-, but not TBK1- or IRF3-, induced IFN-β signaling 
activation and IFN-β expression, suggesting TRIM14 promotes IFN-I signaling probably through 
targeting RIG-I and MAVS (Figures 4I and 4J). Indeed, co-IP experiments revealed that TRIM14 
interacted with RIG-I after stimulation but could interact with MAVS even without stimulation 
(Figure 4K). There was no interaction of TRIM14 with MDA5 or laboratory of genetics and 
physiology-2 (LGP2) observed (Figure 4K), indicating that TRIM14 promotes RIG-I signaling 
by targeting RIG-I after stimulation.  
Identification of a WHIP-TRIM14-PPP6C complex that positively regulates RIG-I signaling 
Next, we sought out to identify additional TRIM14 interacting proteins that may participate 
in RIG-I signaling activation. Proteomic mapping methods engineered ascorbic acid peroxidase 
(APEX) proximity biotin-labelling followed by mass spectrometry and the yeast two-hybrid 
screening system were utilized. We identified Werner helicase-interacting protein 1 (WHIP) and 
protein phosphatase 6 catalytic subunit (PPP6C) as potential interactors of TRIM14 (Figure 5A-
E). Of note, PPP6C was also one of our candidates that interacted with TRIM14 in a distinct 
screening system by using APEX2 biotin-labeling [125] mentioned in our previous study [17]. To 
demonstrate their interactions in physiological conditions, we performed immunoprecipitation in 
human monocyte THP-1 cells using a TRIM14 antibody and showed endogenous interactions 
among TRIM14, WHIP, and PPP6C, even without VSV infection (Figures 5F), suggesting pre-
existence of this complex. Confocal imaging analysis further showed that TRIM14 colocalized 
with WHIP and PPP6C as a complex in the cytosol forming punctate structures before stimulation, 
in addition to the nuclear localization of WHIP as expected [126] (Figure 5G). To further support 
the assembly of a WHIP-TRIM14-PPP6C complex, we performed size-exclusion chromatography 
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co-elution experiments and showed that WHIP, TRIM14, and PPP6C were co-eluted in a complex 
with a high molecular mass of approximately 650 kDa (Figure 5H, Mock). Upon VSV infection, 
WHIP, TRIM14, and PPP6C were co-eluted in even higher molecular weight fractions (Figure 
5H, VSV vs. Mock), suggesting that viral infection promotes the assembly of WHIP-TRIM14-
PPP6C with additional molecules, such as RIG-I and/or MAVS. Indeed, we readily detected RIG-
I in the same fractions containing WHIP-TRIM14-PPP6C complexes (Figure 5H, VSV vs. Mock). 
By contrast, TRIM14 deficiency completely disrupted the entire complex, suggesting a crucial role 
of TRIM14 in the assembly of the WHIP-TRIM14-PPP6C complex (Figure 5H, TRIM14 KO vs. 
WT mock). 
To confirm the stimulatory roles of WHIP and PPP6C in IFN-I signaling, we generated 
WHIP KO and PPP6C KO cells by the CRISPR/Cas9 system. We showed a dramatic reduction in 
ISRE-Luciferase activity stimulated by poly(I:C)-LMW and VSV, as well as VSV-induced 
phosphorylation of IRF3 in WHIP KO and PPP6C KO 293T cells (Figures 5I-K). As a result, the 
IFN-β production was significantly decreased in WHIP KO and PPP6C KO THP-1 cells after VSV 
infection (Figure 5L). To further map the TRIM14 domains responsible for the interactions with 
WHIP and PPP6C, we performed immunoprecipitation using FLAG-tagged full-length (FL) and 
truncated TRIM14 (NT, 1-265 aa; CT, 266-442 aa) proteins to detect HA-WHIP and HA-PPP6C. 
We found that WHIP interacted with the N-terminal domain of TRIM14, whereas PPP6C 
associated with the C-terminal domain of TRIM14 and weakly interacted with the N-terminal 
domain of TRIM14 (Figure 5M). Thus, our data uncovered a previously unrecognized role of 
TRIM14 in the assembly of a positive regulatory signalosome, comprising WHIP and PPP6C in 
the modulation of RIG-I-mediated IFN-I signaling.  
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Figure 5. TRIM14 forms a complex with WHIP and PPP6C that promotes RIG-I signaling. 
(A) Schematic depiction of proteomic mapping of TRIM14 interacting candidates through 
APEX2-mediated biotin labeling. APEX2 fused to TRIM14 enables biotin labeling on proteins 
surrounded < 20 nm from TRIM14 in the presence of H2O2 and Biotin-phenol. Biotinylated 
proteins were then affinity-enriched with streptavidin beads. Eluted products were further analyzed 
by mass spectrometry. (B) Fluorescence imaging of co-localization of biotinylated candidates 
stained with a Dylight594-conjugated anti-Streptavidin antibody with EGFP-TRIM14-APEX2 
forming vesicle-like structure in HEK293 cells as illustrated in panel (A). (C) Silver staining and 
immunoblotting of biotinylated binding candidates surrounding TRIM14. Shown on the SDS-
PAGE were samples before (lanes 1-4) and after (lanes 5-8) streptavidin bead-enrichment, as well 
as the eluted samples immunoblotted by HRP-conjugated anti-streptavidin antibody (Streptavidin-
HRP, lanes 9-13). (D) Classification of candidates emerged from proteomic mapping. (E) Yeast 
two-hybrid (Y2H) screening identified WHIP and PPP6C as interactors of TRIM14. (F) Co-IP and 
IB analysis of THP-1 cells infected with VSV for 8 h. (G) Confocal microscopy analysis of WHIP 
(blue), TRIM14 (green), and PPP6C (red) in 293T cells. Below is an enlargement of the area 
outlined on the top. Quantification of WHIP/TRIM14, WHIP/PPP6C, or TRIM14/PPP6C 
correlation (C, right). (H) Extracts of THP-1 cells mock treated or infected with VSV (MOI=1) 
for 12 h were fractionated on a size-exclusion column. The collected fractions (0.5 ml) were used 
for IB analysis with specific antibodies. The size was determined by the elution of calibration 
proteins with known molecular masses (kDa). (I and J) IB analysis of WT and WHIP KO (E) or 
PPP6C KO (F) THP-1 cells infected with VSV for 8 h.  (K) ISRE promoter luciferase assay of 
TRIM14, WHIP, or PPP6C KO 293T cells stimulated with poly(I:C)-LMW or VSV. (L) ELISA 
of IFN-β production in WT, TRIM14 KO, WHIP KO, or PPP6C KO THP-1 cells infected with 
VSV for 12 h. (M) Co-IP and IB analysis of 293T cells transfected with full length (FL), N-
terminus, or C-terminus FLAG-TRIM14 together with HA-WHIP or PPP6C.  Data in (K) and (L) 
are expressed as means ± SD of three independent experiments. *p<0.05, **p<0.01, versus 
controls.  
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WHIP bridges RIG-I with the WHIP-TRIM14-PPP6C complex after stimulation 
Since we demonstrated that TRIM14 formed a complex with WHIP and PPP6C, we 
investigated how the WHIP-TRIM14-PPP6C complex interacts with RIG-I after stimulation. Co-
IP experiments confirmed that WHIP and PPP6C could also interact with RIG-I only after VSV 
infection, while they interacted with MAVS before and after VSV infection (Figures 6A). By 
contrast, there were no interactions of WHIP and PPP6C with MDA5 or LPG2. Consistently, 
confocal microscopy analysis further showed the colocalization of TRIM14, WHIP, and PPP6C 
with RIG-I on mitochondria after poly(I:C)-LMW stimulation (Figures 6B). These results, along 
with data from Figures 1K and 2, further support our conclusion that the WHIP-TRIM14-PPP6C 
complex inducibly interacts with RIG-I, but constitutively interacted with MAVS. 
To further validate the essential component of the TRIM14 complex that mediates the 
interaction with RIG-I after stimulation, we investigated the direct interaction of the WHIP-
PPP6C-TRIM14 complex with RIG-I in the WHIP, TRIM14, and PPP6C KO 293T cells. We 
found that WHIP deficiency blocked the interactions of RIG-I with TRIM14 and PPP6C (Figure 
6C). In addition, TRIM14 KO reduced the interaction of RIG-I with WHIP and blocked the 
interaction of RIG-I with PPP6C (Figure 6C). By contrast, PPP6C deficiency did not affect the 
interactions of RIG-I with WHIP or TRIM14 (Figure 6C). These results suggest that WHIP is the 
most crucial factor that mediates the interaction of RIG-I with TRM14 and PPP6C, while PPP6C 
is not required for their interaction of RIG-I with WHIP and TRIM14. WHIP ablation in 293T 
cells substantially abolished the poly(I:C)-LMW induced association of RIG-I with TRIM14 
punctate structures as well as RIG-I mitochondrial localization (Figure 6D). To determine the 
critical domains of WHIP that mediate interactions with RIG-I, TRIM14, and PPP6C after 
stimulation, we performed co-IP experiments and found that the N-terminal domain of WHIP 
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interacted with RIG-I, while the C-terminal domain is important for the interaction with PPP6C 
and TRIM14 (Figure 6E). These results suggest that WHIP plays a critical role in bridging the 
WHIP-TRIM14-PPP6C complex with RIG-I by interacting with RIG-I using its N-terminal 
domain after stimulation while keeping its interactions with TRIM14 and PPP6C through its C-
terminal domain.  
 
 
 
 
 
  40 
Figure 6. WHIP mediates RIG-I interaction with TRIM14 and PPP6C after stimulation. (A) 
Co-IP and IB analysis of 293T cells transfected with plasmids for WHIP and PPP6C together with 
FLAG-RIG-I, MAVS, MDA5, or LGP2, followed by stimulation (VSV for RIG-I and MAVS; 
EMCV for MDA5 and LGP2) for 8 h. (B) Confocal microscopy of 293T cells stimulated with 
poly(I:C)-LMW for 8 h. Mitochondria were stained using mitotracker. The white arrow indicates 
colocalization. Scale bar: 10 µm. Quantification of TRIM14/RIG-I/Mito, PPP6C/RIG-I/Mito, or 
WHIP/RIG-I/Mito correlation (B, right). (C) The interaction of WHIP-TRIM14-PPP6C 
mitochondrial complex components with RIG-I after poly(I:C)-LMW stimulation for 8 h. 
Interaction of FLAG-RIG-I with HA-WHIP in WT, TRIM14 KO, or PPP6C KO 293T cells (C, 
1). Interaction of FLAG-RIG-I with HA-TRIM14 in WT, WHIP KO, or PPP6C KO 293T cells 
(C, 2). Interaction of FLAG-RIG-I and HA-PPP6C in WT, WHIP KO, or TRIM14 KO 293T cells 
(C, 3). Control was IP with IgG. (D) Confocal analysis of WT and WHIP KO 293T cells stimulated 
with poly(I:C)-LMW for 6 h. Scale bar: 10 µm. Correlation coefficient analyses of TRIM14/RIG-
I, TRIM14/Mito, or RIG-I/Mito (D, below). (E) Co-IP and IB analysis of 293T cells transfected 
with full length (FL), N-terminus (1-245 aa), or C-terminus (246-665 aa) HA-WHIP together with 
empty vector, FLAG-RIG-I, TRIM14, or PPP6C. Data in (B) and (D) are expressed as means ± 
SD of three independent experiments. *p<0.05, **p<0.01, versus controls.  
 
WHIP is required for TRIM14-mediated enhancing effect on RIG-I Signaling and binds to polyUb 
chains on RIG-I lys164  
To further define the detailed mechanisms and physiological function of WHIP, we used 
WT and WHIP KO 293T cells with or without ectopic expression of TRM14 followed by 
poly(I:C)-LMW stimulation or VSV infection. We found that ectopic expression TRIM14 
enhanced ISRE-Luc activities after poly(I:C)-LMW stimulation or VSV infection in WT cells but 
failed to do so in WHIP KO 293T cells (Figure 7A). Similar results were obtained for IRF3 
phosphorylation using WT and WHIP KO cells (Figure 7B). These data suggest that WHIP is 
absolutely required for TRIM14-mediated enhancing effects on RIG-I-mediated signaling. 
A conserved UBD harbored in the N terminus of WHIP has been reported to be capable of 
binding to K63 polyUb chains [118]. We hypothesized that the viral dsRNA induced opening-
conformation of RIG-I and subsequently the K63 ubiquitination of RIG-I might provide the access 
for WHIP to interact with RIG-I through its ubiquitin-binding domain [127, 128]. We, therefore, 
generated a D37A mutant of WHIP, whose ubiquitin-chain-binding ability was greatly impaired 
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[118] and used for co-IP experiments. Although WT WHIP bound to RIG-I, as we expected, we 
failed to detect the interaction of the WHIP D37A mutant with RIG-I after poly(I:C)-LMW 
stimulation (Figure 7C). Consistent with this observation, the WHIP D37A mutant diminished 
TRIM14-stimulated ISRE-Luc activity after poly(I:C)-LMW stimulation (Figure 7D). These 
results indicate that the UBD in WHIP is required for the interaction between WHIP and RIG-I 
and its subsequent function in IFN-I signaling.  
We next tested whether the blockade of the K63 polyUb chains on RIG-I could impair the 
binding of WHIP to RIG-I. We generated RIG-I mutants K99R, K164R, K169R, K172R, and 
K788R (in which the Lys residue was substituted with Arg) to abolish the attachment of polyUb 
chains on RIG-I. We showed that K164R mutant inhibited WHIP- and TRIM14-stimulated ISRE-
Luc activity triggered by poly(I:C)-LMW, compared to other known important lysine residues 
(Figure 7E), suggesting that WHIP binds to the polyUb chains of RIG-I 2CARD domain at the 
K164 site. Furthermore, we showed that WHIP colocalized with RIG-I-2CARD (Figure 7F). 
Consistently, we found that while WHIP could efficiently bind to WT and RIG-I K172R mutant 
after VSV infection, the interaction of WHIP with RIG-I K164R mutant was completely abolished 
(Figure 7G). Further experiments using a WHIP antibody showed that pull-down of ubiquitinated 
RIG-I after VSV infection contained RIG-I with a higher molecular weight, suggesting that WHIP 
binds to ubiquitinated RIG-I through polyUb chains (Figure 7H).  
Since E3 ligase TRIM4 has been shown to be responsible for the K63 ubiquitination of 
RIG-I at the K164 site [50], we next tested whether depletion of TRIM4 could abolish the binding 
of WHIP to RIG-I. We generated TRIM4 depleted 293T cells by TRIM4 shRNA and showed that 
TRIM4 depletion markedly reduced the binding of WHIP to RIG-I, as well as the WHIP-stimulated 
ISRE-Luc activity after stimulation (Figures 7I and 7J). These data suggest that the binding of 
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WHIP to the K63 polyUb chains at the K164 site of RIG-I is a key event to mediate the WHIP-
TRIM14-PPP6C complex-induced activation of RIG-I IFN signaling.  
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Figure 7. WHIP binds to polyUb chains on RIG-I lys164. (A) ISRE promoter luciferase activity 
of WT or WHIP KO 293T cells transfected with empty vector or Myc-TRIM14 followed by 
poly(I:C)-LMW (black bars) or VSV (blue bars) stimulation. (B) IB analysis of WT and WHIP 
KO 293T cells transfected with empty vector or Myc-TRIM14, followed by poly(I:C)-LMW 
stimulation. Quantitative comparison of the p-IRF3 level was analyzed by densitometric scanning 
of blots normalized to β-actin. (C) Co-IP and immunoblot analysis of 293T cells transfected with 
FLAG-RIG-I together with WT or D37A mutant HA-WHIP, followed by poly(I:C)-LMW 
stimulation. (D) ISRE reporter luciferase assay of WT and WHIP KO 293T cells reconstituted with 
empty vector alone, or Myc-TRIM14 alone or combined with HA-WHIP WT or HA-WHIP D37A, 
followed by poly(I:C)-LMW stimulation. ND, not detected. (E) ISRE reporter luciferase assay of 
293T cells transfected with FLAG-RIG-I (WT, K99R, K164R, K169R, K172R, K788R) along 
with empty vector, HA-WHIP, or Myc-TRIM14, followed by poly(I:C)-LMW treatment. (F) 
Confocal microscopy 293T cells transfected with GFP-WHIP and mcherry-RIG-I-2CARD (RIG-
I-N) without stimulation. White, white field. (G) Co-IP and IB analysis of 293T transfected with 
WT FLAG-RIG-I or various RIG-I mutants along with HA-WHIP followed by VSV infection. (H) 
Co-IP and IB analysis of 293T cells infected with VSV for 12 h.  (I) Co-IP and IB analysis of WT 
or TRIM4 depleted 293T cells were transfected with FLAG-RIG-I and HA-WHIP followed by 
poly(I:C)-LMW stimulation for 10 h. (J) ISRE reporter luciferase assay of WT or TRIM4 depleted 
293T cells transfected with empty vector or HA-WHIP, followed by poly(I:C)-LMW stimulation. 
Data in (A), (B), (D-E), and (J) are expressed as means ± SD of three independent experiments. 
*p<0.05, **p<0.01, NS: not significant, versus controls. 
 
WHIP stabilizes RIG-I-dsRNA interaction and promotes RIG-I K63 ubiquitination  
Studies of ATP-dependent viral RNA recognition by RLR and oligomerization of RLR on 
viral RNA reveal the essential role of the ATPase core domain harbored in RLR [129]. We asked 
whether the ATPase activity of WHIP is required for RIG-I signaling. We reasoned that ATPase 
activity of WHIP might act as a feedback to stabilize RIG-I-dsRNA interaction, promote RIG-I 
K63 ubiquitination, and enhance the WHIP-RIG-I interaction. To test our predictions, we 
generated a WHIP ATPase-dead mutant (T294A), in which Thr294, a conserved residue in the 
nucleotide binding motif, was substituted with Ala [130]. Ectopic expression of WT WHIP in 
WHIP KO 293T cells conferred ISRE-promoter activity in response to poly(I:C)-LMW stimulation, 
but the ISRE-Luc activity was markedly inhibited when WHIP-T294A or WHIP-D37A mutants 
were used (Figure 8A), suggesting that the ATPase activity of WHIP is required for regulating 
RIG-I-mediated signaling. 
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To determine the role of ATPase activity of WHIP in RIG-I-dsRNA interaction, we 
performed a pull-down experiment by incubating NeutrAvadin-beads, biotin-labeled poly(I:C)-
LMW or biotin-only along with cell lysates of 293T cells co-transfected with FLAG-tagged RIG-
I and increasing amounts of HA-WHIP WT or HA-WHIP T294A mutant. We found that addition 
of HA-WHIP-WT, but not the HA-WHIP T294A mutant, enhanced binding of FLAG-RIG-I to 
biotin-(I:C)-LMW (Figure 8B). We further showed that that deletion of WHIP potently inhibited 
K63 ubiquitination of RIG-I after VSV stimulation (Figure 8C). To compare the WHIP binding 
(UBD) and WHIP ATPase activity in RIG-I K63 ubiquitination, we reconstituted WHIP KO cells 
with WHIP WT, D37A, and T294A mutants followed by VSV infection and found that whereas 
WT WHIP restored the K63 ubiquitination, T294A and D37A failed to do so (Figure 8D). These 
results suggest that both ubiquitin-binding and the ATPase activity of WHIP are required for RIG-
I K63 ubiquitination. Furthermore, we found that loss of ATPase activity (T294A) markedly 
reduced WHIP-RIG-I interaction, whereas loss of ubiquitin-binding ability (D37A) completely 
blocked WHIP-RIG-I interaction (Figure 8E), suggesting an essential role of ubiquitin-binding 
and a supportive role of ATPase activity in the WHIP-RIG-I interaction. Thus, our data 
demonstrate a role of ATPase activity of WHIP in the stabilization of RIG-I-dsRNA complex and 
RIG-I K63 poly-ubiquitination.  
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Figure 8. WHIP stabilizes RIG-I-dsRNA and promotes RIG-I K63 ubiquitination. (A) ISRE 
promoter luciferase assay of WT or WHIP KO 293T cells transfected with empty vector, HA-
WHIP WT, HA-WHIP D37A or HA-WHIP T294A, followed by poly(I:C)-LMW stimulation. ND, 
not detected. (B) 293T transfected with FLAG-RIG-I along with the indicated amount (ng) of HA-
WHIP (WT) or HA-WHIP (T294A) plasmids. Cell lysates were then incubated with biotin-only 
or biotinylated-poly(I:C)-LMW for 4 h. Pull-down experiments were performed with NeutrAvadin 
beads, followed by immunoblot analysis using anti-FLAG antibody. (C) Co-IP and IB analysis of 
WT or WHIP KO 293T cells transfected with FLAG-RIG-I and HA-K63 ubiquitin plasmids, 
followed by VSV infection for 10 h. (D) Co-IP and IB analysis of WHIP KO 293T cells transfected 
with FLAG-RIG-I and HA-K63 ubiquitin plasmids along with WT, D37A, or T294A WHIP 
followed by VSV infection for the indicated time points. (E) Co-IP and IB analysis of 293T cells 
transfected with WT, D37A, or T294A HA-WHIP along with FLAG-RIG-I, followed by VSV 
infection for 10 h. Data in (A) is expressed as means ± SD of three independent experiments 
(*p<0.05, **p<0.01, NS: not significant, versus controls). 
  46 
PPP6C is responsible for RIG-I dephosphorylation 
Next, we investigated the potential role of the PPP6C in IFN-I signaling. Since PPP6C is 
a phosphatase, we reasoned that PPP6C might be involved in the dephosphorylation of RIG-I, an 
essential step that triggers the RIG-I-mediated signaling activation. To test this hypothesis, we 
incubated FLAG-RIG-I overexpressed 293T cell lysate with an increasing amount of purified 
PPP6C recombinant protein and monitored the RIG-I phosphorylation with and without VSV 
infection. As expected, we observed a decrease of phosphorylated RIG-I after infection, and 
PPP6C treatment further abolished the phosphorylation of RIG-I on both the serine 8 (S8) and 
threonine 170 (T170) sites in a dose-dependent manner (Figure 9A). Consistently, when PPP6C 
KO 293T cells were infected with VSV, the RIG-I phosphorylation at both the S8 and T170 sites 
were dramatically increased, which was accompanied with diminished p-IRF3 activity (Figure 
9B), and thus suggesting that PPP6C plays a positive regulator function in antiviral signaling 
through the dephosphorylation of RIG-I. Mutations in the PPP6C catalytic subunit have been 
reported as drivers for the development of melanoma by compromising the catalytic activity of 
PPP6C [131]. We generated the mutants R85A, K132N, P186S, R264C, and H114Y (with 
increased proteasome-mediated turnover) and tested their expressions and functions in the RIG-I 
activation. As expected, H114Y showed reduced expression compared to the other catalytic 
mutations (Figure 9C) due to its self-degrading effect [131]. Mutations in the catalytic subunit 
abolished the function of PPP6C as revealed by ISRE-Luc activity (Figure 9D). Moreover, the 
phosphatase catalytic subunit has been shown to form a complex with regulatory subunits to 
determine its substrate specificity or subcellular location such as PP1 and its regulatory subunit 
GADD34 [132]. We tested the potential functions of the PPP6 regulatory subunits in RIG-I 
dephosphorylation and RIG-I signaling, including PPP6R1, PPP6R2, and PPP6R3 [133]. We 
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found that only PPP6C, but not the regulatory subunits, could dephosphorylate RIG-I and promote 
poly(I:C)-LMW induced ISRE-Luc activity (Figures 9E and 9F). Since PPP6C functions in RIG-
I dephosphorylation at S8 and T170 sites, we tested whether blocking the phosphorylation sites of 
RIG-I could abolish the function of PPP6C. By generating serine 8 to alanine (S8A) and threonine 
170 to alanine (T170A) mutants, we showed that while RIG-I S8A and T170A still increased RIG-
I signaling activation, as previously reported [7, 134], PPP6C no longer further enhanced the ISRE-
Luc activity compared with RIG-I WT control (Figure 9G). These data suggest that PPP6C acts 
as a positive feedback regulator by dephosphorylating RIG-I. To test whether the effect of PPP6C 
on RIG-I relies on the assembly of the TRIM14-WHIP signalosome complex, we overexpressed 
PPP6C in WT, TRIM14 KO, and WHIP KO 293T cells. PPP6C failed to stimulate ISRE-Luc 
activity when TRIM14 or WHIP was ablated (Figure 9H), indicating that the intact signalosome 
of TRIM14-WHIP-PPP6C is indispensable for PPP6C to perform its positive regulatory function.  
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Figure 9. PPP6C is essential for RIG-I dephosphorylation. (A) Cell lysates from mock treated 
or VSV infected 293T cells expressing FLAG-RIG-I were incubated with purified recombinant 
HA-tagged PPP6C protein (0, 50, 100 ng) for 2 h followed by co-IP with FLAG-beads. Elutes 
from beads were subjected to immunoblot analysis with the indicated antibodies. Quantitative 
comparison of p-S8-RIG-I and p-T170-RIG-I level were analyzed by densitometric scanning of 
blots and normalized to total FLAG-RIG-I (right). (B) Co-IP and IB analysis of WT or PPP6C 
KO 293T cells transfected with FLAG-RIG-I followed by VSV infection. (C and D) Immunoblot 
analysis (C) and ISRE reporter luciferase activity (D) 293T cells transfected with HA-PPP6C WT 
or mutants, followed by poly(I:C)-LMW stimulation. (E and F) Co-IP and IB analysis (E) and 
ISRE luciferase reporter activity (F) of 293T cells transfected with empty vector, PPP6C, PPP6R1, 
PPP6R2 or PPP6R3, followed by VSV infection. (G) ISRE luciferase reporter assay of 293T cells 
transfected with empty vector, FLAG-RIG-I WT, S8A, or T170A mutants along with empty vector 
or HA-PPP6C. (H) ISRE luciferase reporter assay of WT, TRIM14 KO, or WHIP KO 293T cells 
transfected with empty vector or the HA-PPP6C, followed by poly(I:C)-LMW stimulation. Data 
in (A), (D) and (F-H) are expressed as means ± SD of three independent experiments. *p<0.05, 
**p<0.01, NS: not significant, versus controls. 
 
TRIM14-MAVS interaction is essential for mitochondria-association of WHIP-TRIM14-PPP6C 
complex 
Since we had investigated the interaction and molecular mechanisms of the WHIP-
TRIM14-PPP6C complex and RIG-I in an inducible manner, we next examined the endogenous 
interactions between MAVS and the WHIP-TRIM14-PPP6C complex in THP-1 cells. We 
observed a stable association of MAVS with these proteins before and after VSV infection (Figure 
10A), suggesting that the MAVS platform might be crucial for the cellular localization of the 
WHIP-TRIM14-PPP6C complex. Consistent with these results, we observed, by confocal 
microscopy analysis, the colocalization of WHIP, TRIM14, and PPP6C with MAVS (Figure 10B). 
To understand how the TRIM14 complex interacts with MAVS, we studied the interactions of 
each component in the TRIM14 complex with MAVS using various KO cell lines. We found that 
TRIM14 KO abolished the interactions of MAVS with WHIP and PPP6C (Figure 10C), 
suggesting that TRIM14 is a key regulator of their interactions. Consistently, fluorescent confocal 
microscopy analysis revealed that co-localization of TRIM14, PPP6C, and WHIP with MAVS was 
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impaired in TRIM14 KO cells, compared to WT (Figures 10D). We hypothesized that TRIM14-
MAVS interaction might provide a mitochondrial docking platform for WHIP-TRIM14-PPP6C. 
To test this, we isolated mitochondrial and cytosol/nuclear fractions, and detected all three proteins 
in the isolated mitochondrial fraction, compared to the cytosol and nuclear-combined fraction 
(Figure 10E).  
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Figure 10. Mitochondrial WHIP-TRIM14-PPP6C complex bridges RIG-I and MAVS. (A) 
Co-IP and IB analysis of THP-1 cells infected with VSV for the indicated time points. (B) Confocal 
microscopy of 293T cells without stimulation. Scale bar: 10 µm. White arrows indicate 
colocalization. (C) The interactions of WHIP-TRIM14-PPP6C mitochondrial complex 
components with MAVS. Interaction of FLAG-MAVS with HA-WHIP in WT, TRIM14 KO, or 
PPP6C KO 293T cells (C,1). Interaction of FLAG-MAVS with HA-TRIM14 in WT, WHIP KO 
or PPP6C KO 293T cells (C,2). Interaction of FLAG-MAVS and HA-PPP6C in WT, WHIP KO, 
or TRIM14 KO 293T cells (C,3). IP with IgG was used as a control. (D) Confocal microscopy 
analysis of the colocalization of WHIP (green), TRIM14 (green), or PPP6C (green) with MAVS 
(red) in WT or TRIM14 KO 293T cells. Scale bar: 10 µm. Colocalization was outlined by the box. 
Quantification of TRIM14/MAVS, PPP6C/MAVS, or WHIP/MAVS correlation in WT and 
TRIM14 KO cells (D, right). (E) Cell fractions from THP-1 cells were isolated and subjected to 
immunoblot analysis with the indicated antibodies. Cytochrome C (Cyto C) marks mitochondria; 
β-actin was used as a cytosolic marker. C+N, cytosol and nucleus; M, mitochondria. (F) Confocal 
microscopy of WT, MAVS KO, or TRIM14 KO 293T cells. White arrows indicate colocalization 
of WHIP, TRIM14, PPP6C with mitotracker. Scale bar: 10 µm. Quantification of WHIP/TRIM14, 
WHIP/PPP6C, TRIM14/PPP6C, WHIP/Mito, TRIM14/Mito, PPP6C/Mito correlation in WT, 
MAVS KO and TRIM14 KO cells (F, right). (G) Co-IP and IB analysis of WT, WHIP KO, TRIM14 
KO, or PPP6C KO 293T cells infected with VSV for 8h. (H) IB analysis of RIG-I expression in 
cell fractions isolated from THP-1 cells with or without VSV infection for 8h. Lane 1-2, 5-6 empty 
vector; Lane 3-4, 7-8 overexpressing WHIP. Cytochrome C (Cyto C) marks mitochondria; β-actin 
was used as a cytosolic marker. C, cytosol; M, mitochondria. (I) Co-IP and IB analysis of 293T 
cells stably expressing FLAG-RIG-I infected with VSV for the indicated time points. (J) Co-IP 
and IB analysis of WT or MAVS KO 293T cells transfected with FLAG-RIG-I along with GFP-
TRIM14, HA-WHIP, and Myc-PPP6C, followed by VSV infection for 8 h. Data in (D) and (F) are 
expressed as means ± SD of three independent experiments *p<0.05, **p<0.01, NS: not significant, 
versus controls. 
 
Notably, TRIM14 was predominantly in the mitochondrial fraction, while WHIP and PPP6C were 
detected in the mitochondrial and cytosol/nuclear fractions. To demonstrate that the WHIP-
TRIM14-PPP6C is indeed a mitochondrial complex associated with MAVS, we performed 
confocal imaging using WT and MAVS KO 293T cells. We found that MAVS deletion impaired 
the interaction of WHIP with TRIM14 and PPP6C and excluded the WHIP-TRIM14-PPP6C 
complex from mitochondria (Figure 10F, MAVS KO vs. WT), but did not affect WHIP-TRIM14 
and TRIM14-PPP6C interactions. Notably, TRIM14 deletion impaired the colocalization of WHIP 
and PPP6C as well as the mitochondrial localization of WHIP and PPP6C (Figure 10F, TRIM14 
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KO vs. WT). Together, our data suggest that TRIM14-MAVS interaction is critical for the WHIP-
TRIM14-PPP6C complex docking on the mitochondria. 
Next, we examined whether the WHIP-TRIM14-PPP6C complex was critical in mediating 
the RIG-I translocation to the MAVS platform on mitochondria. We first observed the reduction 
of RIG-I-MAVS interaction in WHIP KO or TRIM14 KO 293T cells (Figure 10G). In addition, 
ligand-stimulated mitochondrial translocation of RIG-I was greatly enhanced by the 
overexpression of WHIP (Figure 10H), indicating that the WHIP-TRIM14-PPP6C complex is 
essential for RIG-I mitochondria translocation and interaction with MAVS. To examine the 
sequential events involving WHIP-TRIM14-PPP6C complex interaction with MAVS and RIG-I 
during viral infection, we treated FLAG-RIG-I stably expressed 293T cells with VSV at different 
time points, and found that RIG-I interaction with WHIP, TRIM14, PPP6C, and MAVS occurred 
at 120 min (Figure 10I). Moreover, the interaction of RIG-I with TRIM14, WHIP, or PPP6C was 
abolished in MAVS deficient 293T cells (Figure 10J), suggesting that the MAVS platform is 
important for the binding of this complex to RIG-I after viral infection. Our data suggest that 
MAVS provides an essential mitochondrial platform for the membrane association of WHIP-
TRIM14-PPP6C complex, and for the modulation of RIG-I activation and translocation to promote 
antiviral IFN-I signaling. 
Discussion 
In this study, we uncovered how the assembly of a mitochondrial MAVS-associated 
WHIP-TRIM14-PPP6C complex interacts with RIG-I after viral infection and positively regulates 
RIG-I-mediated innate antiviral signaling. We examined the spatial organization of the WHIP-
TRIM14-PPP6C complex and how it operates within the RIG-I pathway, between RIG-I and 
MAVS, to direct downstream signaling. Our results demonstrate that WHIP mediates the 
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interactions of RIG-I with TRIM14 and PPP6C, while TRIM14 acts as a co-factor of MAVS to 
provide a mitochondrial docking-platform for WHIP and PPP6C. 14-3-3ε has been proposed as an 
essential component of the RIG-I translocation complex at the early stage of RIG-I conformational 
change induced by dsRNA binding [113]. We report an independent mechanism in the regulation 
of RIG-I mitochondria translocation. Specifically, K63 polyUb chains at RIG-I K164 provide an 
essential “ubiquitin-message” for RIG-I cytoplasm-to-mitochondria translocation and RIG-I-
MAVS interaction mediated by the ubiquitin-binding domain of WHIP [118]. Importantly, 
unraveling how the ubiquitin-message is recognized also provides a safety checkpoint, as aberrant 
ubiquitin-mediated signaling contributes to uncontrollable IFN-I signaling activation and tumor 
formation [135].  
The conserved ATPase domain of RIG-I is important for ATP-driven viral RNA binding 
and the discrimination of self/non-self RNA [136-138]. ZAPS has been reported to stabilize the 
RIG-I-RNA complex through ATPase activity [139]. Here we propose that the WHIP ATPase 
domain promotes WHIP-RIG-I interaction and supports the formation of RIG-I-dsRNA complex. 
Mutational and ISRE-Luc activity analyses demonstrate that the WHIP T294A mutant, which had 
a loss of ATPase activity, failed to promote RIG-I-dsRNA interaction compared to WT WHIP, 
suggesting a physiological role for WHIP interacting with RIG-I. As shown by the reduction of 
K63 ubiquitination in WHIP KO cells, we propose that WHIP has a role in RIG-I ubiquitination: 
most likely occurring either through 1) the spatial occupation that inhibits the cleavage of K63 
poly-ubiquitin chains by deubiquitinases, 2) stabilizing RIG-I/E3 ligase interaction, or 3) enhanced 
viral RNA-binding.  
Serving as an auto-inhibitory mechanism, the N-terminus of RIG-I is highly 
phosphorylated by PKC [7]. RIG-I can be activated by PP1α or PP1γ through dephosphorylation 
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after RNA binding, which can be suppressed again through feedback-induced phosphorylation by 
DAPK1 [116]. Thus, the S8 and T170 phosphorylation status is regulated by dynamic regulatory 
mechanisms. In our study, we uncovered an additional phosphatase PPP6C, but not the regulatory 
subunit PPP6R, in the positive feedback regulation of RIG-I CARD dephosphorylation, whose 
function is independent of PP1. Moreover, we demonstrated that an intact WHIP-TRIM14-PPP6C 
signalosome was necessary for RIG-I dephosphorylation by PPP6C, because of deletion of either 
WHIP or TRIM14 impaired PPP6C-stimulated ISRE-Luc activity. Importantly, as a positive 
regulator in IFN-I signaling, PPP6C might provide a potentially important link between 
inflammation and the role of PPP6C in cancer progression and tumor immunity [64, 119, 120, 
140]. 
Based on our findings, we propose a working model for the WHIP-TRIM14-PPP6C 
signalosome in mediating RIG-I activation and innate immune signaling transduction (Figure 11). 
The mitochondrial WHIP-TRIM14-PPP6C complex constitutively interacts with MAVS through 
the interaction between TRIM14 and MAVS and interacts with RIG-I in an inducible manner (i.e., 
only after poly(I:C) stimulation or VSV infection). Upon viral infection, WHIP protein (UBD in 
the N-terminus) interacts with RIG-I to stabilize RIG-I-dsRNA complex and promote RIG-I K63 
ubiquitination through ATPase activity. WHIP promotes the translocation of RIG-I to MAVS 
mitochondrial platform. The PPP6C of the WHIP-TRIM14-PPP6C complex can dephosphorylate 
RIG-I to maintain the RIG-I activation. Thus, this signalosome plays critical roles in activating the 
RIG-I function and bridging RIG-MAVS interaction for IFN-I signaling and antiviral immunity. 
Targeting WHIP-TRIM14-PPP6C function may offer attractive therapeutic strategies to modulate 
immune signaling for the control of RNA virus infection. 
  56 
 
Figure 11. Working model for WHIP-TRIM14-PPP6C in RIG-I signaling. A proposed model 
illustrates how WHIP-TRIM14-PPP6C complex functions in RLR-mediated signaling. In 
uninfected cells (no stimulation), WHIP-TRIM14-PPP6C complex interacts with MAVS and 
docks on the mitochondrial membrane. Upon VSV or SeV infection, binding of dsRNA by RIG-I 
leads to conformational change and K63 poly-ubiquitination at the Lys164 site. WHIP UBD binds 
to K63 polyUb chains of RIG-I at the Lys164 site and bridges ubiquitinated RIG-I and TRIM14-
MAVS complex. ATPase activity of WHIP stabilizes RIG-I-dsRNA interaction. Phosphatase 
activity of PPP6C further augments RIG-I activation. 
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CHAPTER III  
MYELOID LOSS OF BECLIN1 ENABLES THE MALIGNANT TRANSFORMATION 
OF PD-L1+ PRECURSOR B CELLS 
 
Introduction 
Autophagy has been recognized as a key intracellular degradation and recycling machinery 
for maintaining cellular homeostasis, whose dysregulation may lead to cancer and other diseases 
[141]. Beclin-1 (Becn1) acts as the core component of the class III phosphatidylinositol 3-kinase 
Vps34 complex, which is critical for the initiation of autophagy and autophagosome formation 
[80]. Becn1 functions as a tumor suppressor to prevent tumor development, as monoallelic deletion 
of Becn1 results in the spontaneous tumor formation including lymphoma [142, 143]. However, 
Becn1 haploinsufficiency also reduces spontaneous renal tumor formation in Tsc2+/- mice [144]. 
The critical role of Becn1 in tumorigenesis by autophagy-dependent or -independent mechanisms 
using cell-type specific deletion mouse model remains unclear. 
Inflammation triggered by the activations of innate immune signaling, including NF-κB, 
type I interferon (IFN) and inflammasome, leading to the expression of pro-inflammatory 
cytokines, allowing tumor cells to evade immune surveillance [145, 146]. For example, 
macrophage-derived TNF-α induces expression of CSN5 to stabilize immune checkpoint molecule 
PD-L1 [78]. Cdk5 promotes IFN-γ-induced PD-L1 expression by suppressing PD-L1 
transcriptional repressors interferon regulatory factors IRF2 and IRF2BP2 [69]. Autophagy-related 
genes have well-established functions in modulating cancer cell signaling in both autophagy-
dependent and -independent manner [81, 101]. However, the non-cell-autonomous role of 
myeloid-specific Becn1 in the regulation of tumor inflammation remains largely unknown.  
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Intensive studies have been focused on the cause of B cell malignancies by aberrant 
precursor (pre)-B cell receptor (pre-BCR) and BCR signaling, chromosomal translocation and 
oncogenic mutations within cancer cells [147]. However, recent studies show that tumor cells rely 
on the interactions of myeloid cells (Gr-1+CD11b+ neutrophils and F4/80+CD11b+ macrophages) 
and tight-junction (TJ) molecules that constitute the tumor microenvironment [148, 149]. B-cell 
lymphomas can escape T-cell-mediated cellular cytotoxicity by exploiting the inhibitory PD-1/PD-
L1 immune checkpoint [150]. Recruitment of these myeloid populations has been proposed as 
possible mechanisms for immune suppression in the tumor microenvironment [76, 79]. However, 
signaling pathways that regulate the properties of tumor-supportive myeloid cells and factors that 
drive the metastatic tumor progression through the expression of immune checkpoint molecules 
are still elusive. 
In this study, we identify Becn1 as a negative regulator of p38 signaling in an autophagy-
independent manner. Importantly, we showed a high incidence (~25%) of spontaneous pre-B cell 
lymphoma development in mice with myeloid-specific ablation of Becn1. Tumor-bearing mice 
exhibited loss of tight-junction molecules but an accumulation of neutrophils with B cell helper 
properties at the invasive edge of tumor cells through CXCR3/CXCL9 chemotaxis. Persistent 
activation of STAT3 and NF-kB p52 signaling and robust induction of MHC class I, PD-L1, and 
anti-apoptotic genes were evident in these high-metastatic tumors. Analysis of human pre-B acute 
lymphoblastic lymphoma/leukemia patient samples revealed the low expression of Becn1 in 
tumor-infiltrated neutrophils. Our findings identify a previously unrecognized role of Becn1 in 
immune checkpoint regulation of malignant pre-B cells.  
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Methods and Materials 
Animals and in vivo procedures 
Adult C57BL/6 (CD45.2) and Boy/J (CD45.1) mice were obtained from the Jackson 
Laboratory. Becn1flox mice (Knockout Mouse Project Repository [KOMP]) were crossed with 
lysozyme-Cre (Lyz2-Cre) mice (Jackson Laboratory) to obtain Becn1ΔM mice on the C57BL/6 
background. Mouse genotyping primers to detect WT and flox/flox mutant were as follows: 1) 
Becn1-1R: 5’- GCGGATCCCTGAGTTCTAGACTAACC-3’; 2) Becn1-1F (ttR): 
CTCCCAATGCTGGGATTAAAGACG-3’; and 3) Becn1-2R (F): 
TTGTACCGTGATTTAGGGCGTTTGC-3’. Becn1ΔM mice were bred with Mapk14 flox mice 
(provided by Y. Wang, UCLA, and H. Jiang, Boehringer-Ingelheim) [151] or Il6 -/- mice (Jackson 
laboratory) to generate Becn1ΔM:Mapk14ΔM and Becn1ΔM:Il6-/- mice, respectively. To generate 
Becn1 and Map3k3 double knockout BM chimeric mice, deletion of Map3k3 was achieved by the 
clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 system [152].  We used 
the following single-guide (sg) RNA sequences to target exon1 of Map3k3: 1) sg-Map3k3-
Forward, 5′-CACCGACCGGGTTCGTCGGCTCATC-3′ and 2) sg-Map3k3-Reverse, 5′-
AAACGATGAGCCGACGAACCCGGTC-3’. And non-targeting mouse sgRNA as control: 1) 
sg-Control-Forward, 5’-CACCGGCGAGGTATTCGGCTCCGCG-3’ and 2) sg-Control-Reverse, 
5’-AAACCGCGGAGCCGAATACCTCGCC-3’. Total BM was isolated from the femur and tibia 
of 6 to 10-week-old female C57BL/6 wild-type mice or Becn1ΔM mice. BM was subjected to 
erythrocyte lysis (BD PharmLyse, BD Bioscience), followed by magnetic bead selection of cKit-
positive cells using CD117 MicroBeads (Miltenyi Biotec). Prior to flow sorting using BD 
FACSAria II, CD117-selected cells were stained with APC-labeled cKit (eBioscience), PE-labeled 
Sca1 (BioLegend), PacificBlue-labeled Gr1, CD11b, B220(CD45R), Ter119, and CD3 (all from 
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eBiosciences). LSK cells were cultured in StemPro®-34 SFM complete medium (ThermoFisher) 
supplemented with 50 ng/ml murine Thpo and 50 ng murine Scf (both Life technologies) for 48 h 
and then transduced with concentrated lentiviral supernatant in presence of 2 µg/ml Polybrene. 24 
h post-transduction cells were collected and intravenously injected into lethally irradiated (950 
cGy) 6 to 10-week-old female C57BL/6 mice (Jackson Laboratory). Since the CRISPR-Cas9 
genotyping data provided only a 'snapshot' of the polyclonal cell population genotype, the 
possibility that not all alleles had been targeted by this approach could not be ruled out. For BM 
chimeras, approximately 1.5 x 106 total BM cells from CD45.1+ donors were mixed with 1.5 x 106 
total BM cells from adult WT (CD45.2+) or Becn1ΔM (CD45.2+) mice and then were transferred 
into adult WT CD45.1 mice that had been exposed to 950 cGy. Chimeras were analyzed at least 6 
weeks after reconstitution. To study in vivo endotoxicity, mice received intraperitoneal (i.p.) 
injection of LPS (25–30 mg/kg), and blood samples were collected to assay plasma cytokine 
concentrations. Animal experiments were approved by the Institutional Animal Care and Use 
Committee of Houston Methodist Research Institute.  
RNA-seq 
Total RNA was used for mRNA isolation and cDNA library generation with miRNeasy 
micro Kit (Qiagen). On-column DNase digestion (DNase-Free DNase Set, Qiagen) was performed 
according to manufacturer protocols to prevent genomic DNA contamination. RNA and library 
preparation integrity were verified using a 2100 BioAnalyzer system (Agilent). Ribosomal RNA 
depletion was performed following the low input protocol by RiboMinus Eukaryote System v2 
(ThermoFisher) with 500 ng total RNA input. Finally, libraries were prepared using the Ion Total 
RNA-Seq Kit v2 (ThermoFisher) with minor changes to the standard protocol. These included 
lower amplification cycles and the usage of entire fragmented RNA for cDNA synthesis. For the 
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sequencing reactions, an Ion Torrent Proton platform with V3 chemistry (Ion PI Template OT2 
200 Kit v3, ThermoFisher) and PIV2 Chips (Ion PI™ Chip Kit v2, ThermoFisher) were used. The 
experiment was performed on two chips containing two biological replicates per condition 
(wt1/mt1 on chip A and wt2/mt2 on chip B) resulting in 163 million total reads and at least 40 
million reads per library. Base-calling was performed on Ion Torrent suite software. Raw 
sequencing reads in FASTQ format were aligned to the UCSC mouse reference genome (mm10) 
using TOPHAT21 [153]. Differentially expressed genes were identified using DESeq2 version 
1.62 [154]. Only genes with a minimum fold change of +/− 2, a maximum Benjamini-Hochberg 
corrected p-value of 0.05, and a minimum combined mean of 5 reads were classified as having 
significant differential expression. Gene set enrichment analysis (GSEA) software was used to 
perform GSEA against the GSEA database was used [155]. Data were also analyzed with Ingenuity 
Pathway Analysis (IPA) software (Ingenuity Systems, www.ingenuity.com).  
Isolation of immune cells 
BM cells were isolated from the tibia and femur and cultured in RPMI1640 medium with 
10% FBS, 1% penicillin-streptomycin, 55 mM β-mercaptoethanol, and 10% L929 conditioned 
media containing macrophage-colony stimulating factor for 5 days for BM-derived macrophages 
(BMDMs), 20 ng/mL murine GM-CSF and 10 ng/ml IL-4 for 6–8 days for conventional DCs. 
Peritoneal macrophages were obtained by injecting mice Intraperitoneally (i.p.) with 4% (v/v) 
thioglycollate (Beckton Dickson) and peritoneal cavities were flushed after 3 days with RPMI 
1640 media with 2% FBS. Mouse CD4 cells were isolated from SP or LN by using Dynabeads® 
untouched mouse CD4 cells kit (ThermoFisher). 108 cells/mL of splenocytes and LN cells were 
blocked with heat inactivated FBS and antibody mix against CD8, B220, CD11b, Ter-119 and 
CD16/32. After 20 min incubation at 4°C, cells were washed with isolation buffer (PBS (Ca2+ and 
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Mg2+ free) supplemented with 0.1% BSA and 2 mM EDTA) and incubated with pre-washed mouse 
depletion dynabeads for 15min at room temperature (RT). Resuspended beads-bound cells by 
gently pipetting were placed in the magnet for 2min. Untouched CD4+ T cells in the supernatant 
were then collected. Similarly, total B cells were isolated from tumor, LN, SP or BM by using 
mouse CD45R (B220) microbeads (Mitenyi Biotec) or PE-positive selection beads with PE-B220 
antibody. Peripheral neutrophils were obtained from the peritoneal cavity by i.p. injection of mice 
with 2 ml 4% (v/v) thioglycollate for 4 h followed by collection of peritoneal exudates with RPMI 
1640 media with 2% FBS. Cells were stained with anti-Gr-1-PE (eBioscience) and purified with 
PE-positive selection magnetic beads (Stem Cell Technologies), or using EasySep Mouse 
Neutrophil Enrichment Kit (Stem Cell Technologies) to remove non-neutrophil populations. 
Tissue infiltrated neutrophils were purified from intraparenchymal pulmonary or LN cell 
suspensions using similar isolation method as peritoneal neutrophils. Briefly, for lung neutrophil 
isolation, the chest of the mouse was opened, and the lung vascular bed was flushed with 2–3 ml 
of pre-chilled PBS injected into the right ventricle. Lungs were excised to avoid the paratracheal 
LNs and thymus and washed twice in RPMI 1640 media supplemented with 
penicillin/streptomycin. The excised lungs were minced finely, and the tissue pieces were placed 
in RPMI 1640 medium containing 2% FBS, 20 U/ml collagenase, and 1 g/ml DNase. Following 
incubation for 60 min at 37°C, any remaining intact tissue was disrupted by passage through a 21-
gauge needle. Tissue fragments and the majority of dead cells were removed by rapid filtration 
through a glass-wool column, and cells were collected by centrifugation. Cells were subjected to 
the enrichment using anti-Gr-1-PE and PE-positive selection or EasySep Mouse Neutrophil 
Enrichment Kit. 
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Immunoprecipitation and immunoblot analyses 
For immunoprecipitation, whole-cell lysates were incubated overnight with indicated 
antibodies plus protein A and G beads (Pierce). For immunoprecipitation with anti-FLAG, anti-
FLAG agarose gels were used. Beads were then washed five times with low-salt lysis buffer 
(50mM HEPES,15mM NaCl, 1mM EDTA, 1.5mM MgCl2, 10% Glycerol, 1% Triton X-100), and 
immunoprecipitates were eluted with 4 x SDS loading buffer. Immunoblotting was performed by 
resolving protein lysates on SDS-PAGE gels, followed by a transfer to nitrocellulose membranes 
(Bio-Rad), and further incubating membranes with indicated antibodies overnight. For all blots, 
EMD Millipore Luminata Western HRP Chemiluminescence Substrate was used for protein 
detection. 
Flow cytometry 
Cell surface staining, intracellular cytokine staining, flow cytometry, and cell sorting were 
performed as described previously [124]. Single-cell suspensions were obtained from tissues and 
stained for 30 min with indicated antibodies. Flow cytometric analysis was performed with BD 
LSRII Flow Cytometer (Becton Dickson), and data were analyzed by BD FACSDiva software. 
Cytokine release assay 
Cell supernatants or sera were collected at indicated time points after stimulation with LPS 
with or without ATP. Cytokine concentrations were measured by ELISA with anti-mouse TNF-α, 
IL-6, IL-1β, IL-17A, IL-17F, IL-21, IL-22, and BAFF antibodies. ELISAs were performed 
according to the manufacturer's instructions. In brief, 96-well plate was pre-coated with the capture 
antibody (1:500 in coating buffer) at 4°C overnight. On the next day, the plate was washed with 
PBS/0.1%Tween 20 and blocked with 1%BSA/PBS diluent buffer for 2 h at RT. Diluted 
supernatants and cytokine standards were then applied to the plate and incubated for 2 h at RT. 
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The plate was then washed and incubated with biotin-conjugated detection antibody (1:1000 in 
1%BSA/PBS diluent buffer) for 1 h at RT. The plate was then washed and incubated with poly-
HRP streptavidin (1:5000 in diluent buffer, Thermo Scientific) for 30 min. The plate was washed 
again and finally incubated with the tetramethylbenzidine substrate solution (Sigma-Aldrich).  The 
reaction was stopped using 2 M H2SO4. Absorbance of each well was recorded by Synergy™ 2 
plate reader (Biotek) at 450nm. The absorbance of the standard sample was used to construct the 
standard curve. 
Hematological and histological analysis 
Complete peripheral blood counts were performed with an automated hematology analyzer 
(Hemavet 850; Drew Scientific). For whole BM sections, specimens were decalcified in (8%) 
hydrochloric acid/ (8%) formic acid working solution overnight, followed by neutralization by 
ammonia solution for 30 min and embedded in paraffin. Embedded BM blocks were sliced and 
stained with H&E for conventional morphological assessment. For cytocentrifugation 
preparations, BM cells were subjected to red blood lysis in ACK buffer (0.15 mM NH4Cl, 1 mM 
KHCO3, and 0.1 mM Na2EDTA). Between 2 - 5 × 105 cells were suspended in 100 µl PBS, loaded 
onto disposable Cytofunnel chambers, and centrifuged for 4 min at 400 RPM using a CytoSpin III 
cytocentrifuge (Shandon). For May-Grünwald Giemsa stain, cytocentrifuged samples were stained 
in May-Grünwald solution (MG500; Sigma-Aldrich) for 2 min and in Giemsa (GS500, 5% 
solution in water; Sigma-Aldrich) for 12 min, followed by two washes in distilled water for 30 s. 
Thereafter, samples were cytocentrifuged, counterstained with May-Grünwald solution for 10 s 
and washed in water. Slides were coverslipped using Permount and analyzed by brightfield 
microscopy. IHC staining was performed using the streptavidin-biotin-peroxidase complex 
method using Vectastain Elite ABC kit and DAB peroxidase (HRP) substrate kit. Negative control 
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staining was performed using mouse, rabbit, or rat immune sera instead of the primary antibodies. 
Sections of human B cell lymphoblastic leukemia/lymphoma tissues were obtained from Dr. James 
You (UT MD Anderson Cancer Center, Houston, TX), including 10 pre-B ALL in LN or BM and 
6 reactive LN or BM controls. Immunofluorescence assays and confocal microscopy were 
conducted using fluorescent secondary antibodies. Samples were visualized using Nikon Eclipse 
Ti-E microscope. All acquired images were analyzed using the Nikon NIS-Elements AR package 
or the ImageJ (NIH) software. 
In vivo cell depletion 
Monocyte and macrophage depletion was performed by i.v. injection of 250 µl clodronate-
containing liposomes (Encapsula NanoSciences) on day -1 relative to LPS treatment. Control 
liposomes were used as PBS control. Neutrophil/granulocyte depletion was induced with 
combined 0.5 mg of anti-Gr1 mAb clone 1A8 (BioXcell) and 0.1 mg of RB6-8C5 [156] or with 
PBS controls i.p. injection into mice on days -3, -2, and -1 relative to LPS treatment.  
Real-time RT-PCR analysis 
Total RNA was isolated from cells using RNeasy RNA isolation kit (QIAGEN) and reverse 
transcribed using SuperScript III Reverse Transcriptase (Invitrogen) as per manufacturer’s 
directions.  Quantitative PCR was conducted on the ABI Prism 7000 analyzer (Applied 
Biosystems) using SYBR GreenER qPCR Super Mix Universal (Invitrogen). mRNA levels were 
normalized to Gapdh and relative levels were determined using ΔΔct method.  
GEP of human lymphomas 
Gene expression analysis was performed on datasets from Gene Expression Omnibus 
(GEO, https://www.ncbi.nlm.nih.gov/geo/) including GSE12195, GSE26673, GSE16455, 
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GSE12195, GSE16455, GSE7440, GSE11877. Specifically, we included the following cancer 
types: 16 BL, 18 CLL, 38 FL, 75 DLBCL, 22 MCL, 4 MZL, 306 B-ALL, and 5 naïve cell samples. 
Data was processed by Affymetrix Expression Console. Statistical differences among multiple 
groups were analyzed with one-way analysis of variance (ANOVA) test. Significant differences 
were determined when P value is less than 0.05.  
The DAVID/EASE software was used to establish whether specific cell functions and 
biologic processes, defined according to gene ontology [157], were significantly represented 
among the deregulated genes [158]. 
Results 
Myeloid Becn1 ablation induces splenomegaly and lymphadenopathy with neutrophilia 
To investigate the role of Becn1 in myeloid lineage development and innate immune 
response, we crossed Becn1f/f mice with mice expressing the lysozyme promoter-driven Cre 
recombinase gene (Lyz2-Cre), designated as Becn1ΔM mice. Conditional Becn1 deletions in 
F4/80+CD11b+ peritoneal macrophages (pMAC) and Gr-1+CD11b+ neutrophils were verified by 
polymerase chain reaction (PCR) and immunoblot analyses compared to CD11c+ conventional 
dendritic cells (cDCs), CD4+ T cells, and CD19+ B cells (Figure 12A). Notably, Becn1ΔM mice 
developed splenomegaly and profound enlargement of inguinal, axillary and mesenteric lymph 
nodes (LNs) (Figures 12B and 12C). Histological analysis of spleen sections revealed a marked 
effacement of the splenic architecture with loss of marginal zone barriers and a concomitant loss 
of the clear-cut delimitation between the lymphoid and myeloid parenchyma (Figure 12D).  
Loss of myeloid-specific Becn1 markedly increased the number of Gr-1+CD11b+ 
neutrophils in the bone marrow (BM) and spleen (SP). However, the percentage of F4/80+CD11b+ 
macrophage did not change (Figures 12E and 12F). In addition, we found a significant increase 
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of total spleen B220+ B cells (Figure 12G). Together, our results suggest that neutrophilia in 
Becn1ΔM mice is driven by factors intrinsic to hematopoietic cells, causing accelerated proliferation 
and/or enhanced survival of neutrophil progenitors or mature neutrophils. 
 
Figure 12. Characterization and phenotypic analysis of Becn1ΔM mice. (A) Immunoblot 
analysis of Becn1 protein expression with anti-Becn1 in dendritic cells (DC), peritoneal 
macrophages (pMAC), T cells, B cells, and neutrophils (Neu). (B and C) Spleen size comparison 
between WT and Becn1ΔM mice (B, left) and spleen/ body weight ratio (B, right) and 
lymphadenopathy in Becn1ΔM mice compared with WT control (C), Inguinal(i), axillary(ii), and 
mesenteric(iii) lymph nodes were examined. (D) H&E (hematoxylin & eosin) staining of spleen 
sections from WT and Becn1ΔM/ΔM mice. (E and F) Flow cytometric and statistical analysis of Gr-
1+CD11b+ neutrophils and F4/80+CD11b+ macrophage in bone marrow (E) and spleen (F) of WT 
and Becn1ΔM mice. BM, bone marrow; SP, spleen. (G) A total number of splenic CD45+CD11c+ 
DCs, CD4+ T cells, CD8+ T cells, B220+ B cells, CD11b+F4/80+ macrophages, CD11b+Gr-1+ 
neutrophils obtained from the fraction of each population on the basis of the expression of surface 
marker multiplied by the total number of spleen cells. Data shown are plotted as the mean ± s.d. 
and are representative of three independent experiments. *P <0.05, **P <0.01, NS (not significant) 
vs. corresponding control.   
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Neutrophil Becn1 negatively regulates p38 activation and IL-17-related cytokine  
We next examined TLR-mediated innate immune signaling responses between WT and 
Becn 1-deficient cells and found the increased p38 MAPK activity and slightly reduced IKK 
activation after LPS (a TLR4 ligand) stimulation in neutrophils but not macrophages (Figures 13A 
and 13B). Becn1-deficient neutrophils produced a higher amount of TNF-α and IL-1β, whereas 
pMAC produced higher amounts of TNFα and IL-6 (Figure 13C). Consistently, we observed an 
increase in basal expression of pro-IL-1β in Becn1-deficient neutrophils (Figure 13D). To further 
define the physiological function of Becn1, we show that Becn1ΔM mice died after LPS-induced 
endotoxin shock (30 mg/kg) within 12 h, compared to WT mice that survived for up to 40 h 
(Figure 13E). Consistent with this observation, Becn1ΔM mice had markedly elevated serum 
concentrations of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β after LPS treatment 
(Figure 13F). We found that macrophage depletion did not show a difference in survival after 
LPS-induced septic shock. However, there was significantly prolonged survival in mice depleted 
of neutrophils (Figure 13G), indicating that neutrophils play a dominant role in LPS-induced 
septic shock. These results suggest that Becn1 deletion in myeloid cells enhances the sensitivity 
and severity of LPS-induced septic shock and is associated with increased serum concentrations 
of pro-inflammatory cytokines. To determine the role of Becn1 in the regulation of neutrophil-
mediated innate immune signaling and gene expression, we performed the RNA-seq analysis of 
freshly isolated neutrophils followed by 4h LPS treatment. Interestingly, we observed marked 
upregulation of genes involved in pathways related to inflammation, rheumatoid arthritis and 
inflammatory bowel disease (Figures 13H). These included genes encoding the IL-17 and related 
cytokines, chemokine receptor and neutrophil-chemotaxis, cell metabolism, and neutrophil-
mediated immunity. Consistently, we found elevated serum levels of IL-17A, IL-17F, IL-21 and 
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IL-22 in Becn1ΔM mice (Figure 13I). We next isolated Becn1-deficient neutrophils and peritoneal 
macrophages and treated them with LPS and found significantly higher levels of IL-17A in Becn1-
deficient neutrophils, compared with WT controls or macrophages (Figure 13J). Next, we 
examined the mRNA expression of key lineage transcription factors such as Rorc, Ahr, Irf4, and 
Stat3 that drive IL-17 family cytokine production [159]. Rorc was found to be dramatically 
upregulated, but the other transcription factors such as Ahr, IRF4, and Stat3 in Becn1-deficient 
neutrophils remained unchanged (Figure 13K). RORγt inhibitor GSK805 [160, 161] also 
suppressed the transcription of IL-17 cytokine in Becn1-deficient neutrophils (Figure 13L). 
Together, our results suggest that Becn1 deletion promotes neutrophils to produce IL-17 and 
related cytokines.   
  70 
 
 
 
 
 
 
  71 
Figure 13. Cell type-specific regulation of Becn1 in pro-inflammatory pathways. (A and B) 
WT or Becn1-deficient Neu (A) or pMAC (B) were treated with LPS for the indicated time points, 
followed by immunoblot analysis of phosphorylated IKK (p-IKK), p-p38, p-JNK, p-ERK, p-
STAT3, IKK, p38, ERK, JNK, and STAT3 with cell lysates. (C) ELISA measurement of TNF-α, 
IL-6 and IL-1β production by Neu and pMAC after 100 ng/mL LPS treatment for indicated time 
points. (D) Immunoblot analysis of basal intracellular pro-IL-1β in pMAC and Neu. (E) Survival 
of WT and Becn1ΔM mice (n = 10 per group) after high-dose LPS (30 mg/kg) challenge. (F) Plasma 
concentrations of TNF-α, IL-6, and IL-1β in mice at indicated time points after LPS treatment. (G) 
Survival of WT and Becn1ΔM mice (n = 3 per group) treated with PBS- or clodronate-containing 
liposomes to deplete macrophages or treated with the anti-Ly6G antibody (1A8 and RB6-8C3) to 
deplete neutrophils followed by treatment with high-dose LPS (30 mg/kg i.p.). (H) Heatmap 
representation of genes significantly induced (top) or downregulated (bottom) in neutrophils 
isolated from Becn1ΔM mice compared to WT controls, including neutrophil-mediated immunity 
and IL17 related cytokines (purple), chemokine receptor and neutrophil-chemotaxis (green), cell 
metabolism (blue). (I) ELISA measurement of serum IL-17A, IL-17F, IL-21, and IL-22 production 
in WT and Becn1ΔM mice after treatment with LPS (30 mg/kg i.p.). (J) ELISA measurement of IL-
17A production in WT or Becn1-deficient Neu or pMAC after100 ng/mL LPS treatment for 
indicated time points. (K) Quantitative RT-PCR of Becn1, Rorc, Ahr, Irf4, Stat3, Il17a, Il17f, Il21 
and Il22 mRNA in Neu isolated from WT and Becn1ΔM mice. (L) Quantitative RT-PCR of Il17a 
mRNA level in Neu isolated from WT and Becn1ΔM mice treated with LPS for 6 h along with 
DMSO or 0.5 µM GSK805. Data shown are plotted as the mean ± s.d. and are representative of 
three independent experiments. *P <0.05, **P <0.01, NS (not significant) vs. corresponding 
control.   
 
Autophagy-independent degradation of MEKK3 by Becn1 is cell-type specific 
NF-κB and MAPK pathways through MAP3Ks (TAK1, ASK1, MEKK3) activation 
triggers downstream signaling of IKK complex, Erk1/2, p38, and JNK [34]. We tested whether 
Becn1 interacted with key signaling molecules in 293T cells, and found that Becn1 strongly 
interacted with MEKK3 and MKK3, and weakly with IKKβ and NEMO (Figures 14A and 14B). 
Importantly, increased amounts of Becn1 markedly reduced MEKK3 protein in 293T cells (Figure 
14C). Consistently, we found that endogenous MEKK3 was increased in Becn1-deficient 
neutrophils, but not macrophages, with increased p38 phosphorylation (Figures 14D and 14E). 
These results suggest that Becn1 regulates MEKK3 stability and MEKK3-p38 signaling in the 
neutrophils. 
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To understand how Becn 1 regulates MEKK3 for degradation, we showed that proteasome 
inhibitor MG132, but not autophagy inhibitors 3-Methyladenine (3-MA) or chloroquine (CQ), 
blocked Becn1-mediated MEKK3 degradation (Figure 14G), suggesting that Becn1 degrades 
MEKK3 through a proteasome-dependent manner. Protein ubiquitination has emerged as an 
important mechanism to target a protein for proteasomal degradation [162]. By analyzing the 
conjugation of various ubiquitin moieties, we found that Becn1 mediated MEKK3 degradation 
mainly through K48 ubiquitination (Figures 14H and 14I). To identify key lysine residues in 
MEKK3 required for K48 ubiquitination, we substituted a series of lysine residues with arginine 
and found that lysine 299 (K299) residue is essential in Becn1-mediated MEKK3 ubiquitination 
and proteasome degradation (Figures 14J and 14K). These results suggest that Becn1 targets 
MEKK3 for ubiquitination-dependent proteasomal degradation through K299 residue in MEKK3.  
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Figure 14. Becn1 ablation suppresses proteasomal degradation of neutrophil MEKK3. (A 
and B) Screening of Becn1 binding proteins involved in NF-κB and MAPK pathways by 
immunoprecipitation followed by immunoblot analysis in human embryonic kidney (HEK) 293T 
cells. WCL, whole cell lysate.(C) 293T cells transfected with 100 ng HA-MEKK3 along with 
increased amount (0, 100, 250, and 500 ng) of FLAG-Becn1. Cell lysates were subjected to 
immunoblot analysis. (D) MEKK3 protein expression in Becn1-deficient Neu and pMAC 
compared to WT controls were analyzed by immunoblotting with anti-MEKK3 and anti-Becn1 
antibodies. (E) WT or Becn1-deficient neutrophils were treated with LPS for the indicated time 
points, followed by immunoblot analysis of MEKK3, TAK1, p-p38, and Becn1 with cell lysates. 
(F) WT or Becn1-deficient neutrophils were treated with LPS for the indicated time points, 
followed by immunoblot analysis of p-MKK3/6, MKK3/6 p-p38, and Becn1 with cell lysates. (G) 
Immunoblot analysis of 293T cells transfected with HA-MEKK3 along with empty vector or 
FLAG-Becn1 left untreated or treated with proteasome inhibitor MG132 (1 µM) or autophagy 
inhibitors 3-MA (5 mM) or chloroquine (CQ, 10 µM).(H) 293T cells transfected with FLAG-
MEKK3, GFP-Becn1 and HA-Ubiquitin (WT) (UbWT) expression vectors were lysed and 
immunoprecipitated with FLAG-beads followed by Immunoblot analysis with indicated 
antibodies. (I) 293T cells transfected with FLAG-MEKK3, GFP-Becn1 and HA-Ubiquitin mutants 
(K6, K11, K27, K29, K33, K48, and K63) expression vectors were lysed and immunoprecipitated 
with FLAG-beads followed by Immunoblot analysis with indicated antibodies. (J) Immunoblot 
analysis of 293T cells transfected with WT or different mutants of HA-MEKK3 (K69R, K79R, 
K174R, K273R, K299R, K397R, K435R) along with empty vector or FLAG-Becn1. (K) 293T 
cells transfected with FLAG-MEKK3 WT or FLAG-MEKK3 K299R mutant along with GFP-
Becn1 and HA-Ubiquitin K48 expression vectors were lysed and immunoprecipitated with FLAG-
beads followed by Immunoblot analysis with indicated antibodies. 
 
Genetic ablation of p38 or MEKK3 rescues Becn1ΔM mice phenotypes  
To test whether specific deletion of p38 (encoded by Mapk14) or MEKK3 (encoded by 
Map3k3) could rescue the phenotypes and survival in response to LPS-induced septic shock of 
Becn1ΔM mice, we generated Mapk14 f/f x Becn1 f/f x Lyz2-Cre double KO (Becn1ΔM Mapk14ΔM) 
mice. Gross phenotypic analysis revealed that the spleen size of Becn1ΔM Mapk14ΔM mice was 
reduced to a size comparable to WT spleen (Figure 15A). In agreement with these observations, 
the extent of CD11b+Gr-1+ cells (5.26% in BM, 2.77 in SP) of Becn1ΔM mice was reduced to a 
level similar to WT mice (2.32% in BM, 1.17% in SP) in Becn1ΔMMapk14ΔM mice (Figure 15B). 
The serum levels of pro-inflammatory cytokines TNF-α and IL-1β in Becn1ΔM Mapk14ΔM mice 
were reduced to the levels similar to WT control, even though IL-6 production remained at a higher 
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level in both Becn1ΔM Mapk14ΔM mice and Becn1ΔMmice (Figure 15C). Importantly, p38 ablation 
markedly reduced IL-17A production and Rorc mRNA level in Becn1ΔM Mapk14ΔM mice (Figures 
15C and 15D), suggesting that p38 activation in Becn1-deficient neutrophils might control RORγt 
transcription. Importantly, p38 ablation in Becn1ΔM prolonged the survival to the level similar to 
WT mice in response to LPS-induced septic shock, but Becn1ΔM IL-6-/- double knockout mice 
failed to do so (Figures 15E). 
Since mouse Becn1 and Map3k3 are localized on the same chromosome (mm11, 
NC_000077.6), it is difficult to generate Becn1ΔMMap3k3ΔM double KO mice. For this reason, we 
used CRISPR-Cas9 genome editing approach [152, 163] to generate Becn1ΔMMap3k3 cas9 bone 
marrow chimera by deleting Map3k3 in bone marrow hematopoietic stem cells (HSC) isolated 
from WT control or Becn1ΔM mice using Map3k3-specific single guide RNA (sgRNA) or control 
sgRNA. Deletion of Map3k3 in bone marrow chimera was observed by immunoblot analysis of 
peripheral blood cell lysates from Becn1ΔMMap3k3cas9 mice, compared to Becn1ΔM and WT bone 
marrow chimera with control sgRNA (Figure 15F). The LPS-induced phosphorylation of P38 in 
neutrophils isolated from Becn1ΔMMap3k3cas9 mice was significantly reduced (Figure 15G), and 
Becn1ΔM Map3k3cas9 mice were more resistant to LPS when compared to the Becn1ΔM group 
(Figure 15H). These results indicate that p38 or MEKK3 ablation in neutrophils restores 
inflammatory cytokine (TNF-α, IL-1β, and IL-17) production and reduces the hypersensitivity to 
LPS-induced septic shock seen in Becn1ΔM mice. 
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Figure 15. p38 or MEKK3 ablation rescues Becn1ΔM mice phenotype to WT. (A) Spleen size 
(left) and spleen : body weight ratio(right) isolated from WT, Becn1ΔM and Becn1ΔM x Mapk14 ΔM 
mice. (B) Gr-1+CD11b+ neutrophils in WT, Becn1ΔM and Becn1ΔM x Mapk14 ΔM mice were 
analyzed by flow cytometry. (C) TNF-α, IL-6, IL-1β, and IL-17A production in serum from WT, 
Becn1ΔM, and Becn1ΔM x Mapk14 ΔM mice after high dose treatment of LPS (30mg/kg i.p.) were 
analyzed by ELISA. (D) Neutrophils isolated from WT, Becn1ΔM and Becn1ΔM x Mapk14 ΔM mice 
were treated with LPS for 6h. mRNA level of Rorc was determined by quantitative RT-PCR. (E) 
Survival of WT, Becn1ΔM, Becn1ΔM x Mapk14 ΔM and Becn1ΔM x IL-6-/- mice after high dose 
treatment of LPS (30mg/kg i.p.). (F) Peripheral blood from WT, Becn1ΔM, and Becn1ΔM x Map3k3 
cas9 mice was RBC lysed and followed by immunoblot analysis of MEKK3 expression. (G) 
Neutrophils isolated from WT, Becn1ΔM and Becn1ΔM x Map3k3 cas9 mice were treated with LPS 
for the indicated time points, followed by immunoblot analysis of p-p38 and Becn1 with cell 
lysates. (H) Survival of WT, Becn1ΔM, and Becn1ΔM x Map3k3 cas9 mice after high dose treatment 
of LPS (30mg/kg i.p.).Data shown are plotted as the mean ± s.d. and are representative of three 
independent experiments. **P <0.01, NS (not significant) vs. corresponding control.   
 
Spontaneous development of metastatic Pre-B Cells lymphoma in Becn1ΔM mice 
We unexpectedly found exacerbated lymphoproliferation in the cervical lymph nodes in 
20-40% of Becn1ΔM mice (Figures 16A and 16B). Importantly, we showed positive PAX5 and 
B220 staining, but negative for monocyte (Mac-3), macrophages (Mac-1), neutrophils (Ly6G), or 
T cells (CD3) (Figures 16C and 16D). Of note, lung infiltrated tumor cells contained mostly 
PAX5+ B220+ cells, but also PAX5+B220lo/- populations, suggesting the heterogeneity of tumor 
(Figure 16D). Different from B cell lymphoma in Becn1+/- mice that express BCL6 [143], we 
found that the lung infiltrated B220+ tumor cells were BCL6 negative (Figure 16E). 
Using CFSE (carboxyfluorescein succinimidyl ester) labeling, we showed that B cells 
isolated from Becn1ΔM tumor-bearing mice more rapidly proliferated than WT B cells after 
treatment with LPS and IL-4 (Figure 16F). Malignant B cells from Becn1ΔM tumor-bearing mice 
also displayed a unique phenotype of increased expressions of B cell surface markers, including 
CD16/32 [FcΥRIII/FcΥRIIa], activation marker CD80, CD86, and MHC class I (Figure 16G). 
Importantly, we found that elevated percentages of pre-B cells expressing low/intermediate B220 
(16.8% in tumor vs. 0.8% in WT LN) and TdT, likely were cells egressed from BM (Figure 16H-
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J). Sphingosine-1-phosphate receptor (S1P1R) or CXCR4 controls B cell bone marrow egression 
or retention [164, 165]. We sorted B cells from both WT and Becn1ΔM mice and found a marked 
reduction of CXCR4 expression but not S1P1R on B cells from Becn1ΔM mice (Figure 16L), which 
might contribute to the pre-B cell BM egression.  
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Figure 16. MHC-IhiB220lo B cell lymphoma develops in Becn1ΔM mice. (A) Tumor formation 
in cervical lymph node (indicated by red arrows) in Becn1ΔM mice compared to WT mice. T, tumor; 
SLG, sublingual gland; SMG, submandibular gland. (B) Kaplan-Meier curves for tumor-free 
animals were calculated based on the tumor latency of the control (n=21, blue) and Becn1ΔM mice 
(n=40, red). (C) Representative immunohistochemical staining of paraffin-embedded tumor 
sections from Becn1ΔM tumor-bearing mice (n=40) stained with H&E and anti-Mac-3 (monocyte), 
anti-Mac-1 (macrophage), anti-Ly6G (neutrophils), anti-B220 (B cells) and anti-CD3 (T cells). 
(D) Immunohistochemical staining of paraffin-embedded tumor-infiltrated lung sections from WT 
and Becn1ΔM tumor-bearing mice stained with anti-Pax5 and anti-B220 B cell markers. (E) 
Immunohistochemical staining of paraffin-embedded tumor-infiltrated lung sections from WT and 
Becn1ΔM tumor-bearing mice stained with anti-BCL6 (lymph nodes as a positive control). (F) Flow 
cytometric analysis of CFSE-labeled (APC-CFSE) B cells directly sorted from WT and Becn1ΔM 
tumor-bearing mice by PE-positive selection stained with PE-anti-B220 antibody treated with LPS 
and IL-4 for indicated time points. (G) Flow cytometric analysis of surface markers of B cells 
isolated from WT and Becn1ΔM tumor-bearing mice. Significant right-shift markers were indicated 
in red. (H) Flow cytometric analysis of B220 (B cells), CD3 (T cells) and B220+CD3+ (circled) 
populations in WT control and tumor from Becn1ΔM tumor-bearing mice. (I) Flow cytometric 
analysis of B220+ B cells population in bone marrow (BM), spleen (SP) and lymph node (LN) of 
WT and Becn1ΔM tumor-bearing mice. (J) Flow cytometric and statistical analysis of pre-pro B 
(B220+CD43+), pro B (B220+CD43lo), pre-B (B220+CD43-), immature B (B220+CD43-IgM+IgD-
) and mature B (B220+CD43-IgM+IgD+) populations in the bone marrow-derived from WT and 
Becn1ΔM tumor-bearing mice. (K) Immunohistochemical staining of tumor sections with TdT and 
Ki67 antibodies compared to WT controls. (L) Flow cytometric and statistical analysis of marginal 
zone (MZ) B (CD93-CD21hiCD23lo), splenic FO B (CD93-CD21loCD23hi) and B1 B (B220+CD5+) 
populations in the spleen-derived from WT and Becn1ΔM tumor-bearing mice. (M) Quantitative 
RT-PCR of S1p1r and Cxcr4 mRNA in B220+ cells directly sorted from WT (n=5 per group) and 
Becn1ΔM tumor-bearing mice (n=9 per group) by PE-positive selection stained with PE-anti-B220 
antibody. Data shown are plotted as the mean ± s.d. and are representative of three independent 
experiments. **P <0.01, NS (not significant) vs. corresponding control.   
 
Accumulating Becn1-deficient neutrophils interact with B cells 
We consistently observed the colocalization of B cells with a large number of neutrophils 
in the tumor site, lungs, and intestinal Peyer’s patches (Figures 17A-D). To determine the gene 
expression profiling of the tumor and a potential role of neutrophils in the tumor development, we 
extracted total RNA from cervical lymph node tumors for RNA-seq. Significantly increased genes 
in Becn1ΔM mice included inflammatory and B cell-stimulating molecules (Nos2, Ptgs2, Il21, Il1b, 
Il12, Tnfsf13b, Tnfsf18, Nlrp3), chemoattractants (Cxcl9, Cxcr3), neutrophil marker (Ly6g), key 
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mediators of apoptotic cell removal (Figures 17E and 17F). In addition, key transcriptional factors 
Ebf1 and Pax5 shown to be essential for the expansion of B-cell progenitors and acute lymphoid 
leukemia transformation were found to be upregulated [166] (Figure 17F). Notably, 
downregulated cell junction molecules related to leukocyte transendothelial migration (Cdh1, 
Cldn, Tjp1) (Figure 17E) might permit noncanonical interactions between B cells and activated 
myeloid cells. 
Neutrophils have been shown to acquire a B-cell helper phenotype to promote B cell 
expansion and malignant progression through 1) contact-independent cytokine secretion such as 
Tnfsf13b and IL-21; 2) contact-dependent mechanisms such as CD40 and neutrophil extracellular 
traps (NETs) [167-170]. Except for MCL-1 and BCL-2, significant upregulation of B-cell helper 
signature genes was observed in Becn1-deficient neutrophils from tumor-bearing mice (Figure 
17G-I). Auto-activation of p38 was observed in tumor-derived neutrophils, which might contribute 
to IL-21 production (Figures 13 and 17I). Stained Becn1-deficient neutrophils derived from 
tumor-bearing mice with SYTOX impermeable DNA dye revealed increased projection of NETs 
(Figure 17J). Thus, the recruitment of neutrophils by B cells through Cxcl9/Cxcr3 chemotaxis 
(Figures 17E, 17K and 17L) might provide extensive survival signals and inflammatory 
environment, leading to B cell malignant transformation.  
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Figure 17. Becn1 ablation induces B cell helper function of neutrophils. (A) 
Immunofluorescence of tumor section with anti-mac387 (macrophages, cyan), anti-B220 (B cells, 
pink), anti-Ly6G (neutrophils, green), DAPI (nucleus, blue) and anti-Ki67 (proliferation marker, 
red). White line circled area indicates B cell tumor. Original magnification, x40. (B) 
Immunohistochemical staining (B, upper) and two representative immunofluorescent confocal 
images (B, bottom) of paraffin-embedded tumor-infiltrated lung sections from Becn1ΔM tumor-
bearing mice stained with anti-B220 and anti-LY6G (B, upper) or and with anti-MPO (green) and 
anti-B220 (red) antibodies ((B, bottom) showing the interaction of B cells and neutrophils. DAPI, 
DNA-intercalating dye indicates nucleus (blue). (C) Immunohistochemical staining of paraffin-
embedded intestinal Peyer’s patch sections from Becn1ΔM tumor-bearing mice stained with anti-
B220 (C, upper) and anti-Ly6G (C, lower). (D) Representative immunofluorescent staining of 
tumor section with indicated antibodies (D, left) and cartoon illustrates neutrophils surround at the 
edge of B cell zone likely to support B cell proliferation and migration (D, bottom cartoon). (E) 
Log2 ratio of mRNA variations in the tumor from Becn1ΔM mice compared to WT controls by 
RNA-seq.(F) Quantitative RT-PCR for analysis of the mRNA levels of the indicated genes in WT 
lymph nodes, Becn1ΔM lymph nodes (no tumor), and Becn1ΔM lymphomas (n=4 per group).(G) 
Quantitative RT-PCR of B cell helper neutrophils markers: BAFF (Tnfsf13b), Il21, Cd40l, Slp1, 
Nos2, Ido1, Mcl-1, and Bcl-2. (H) BAFF (encoded by Tnfsf13b) and IL-21 production by 
neutrophils directly isolated from WT and Becn1ΔM tumor-bearing mice were analyzed by ELISA 
after in vitro culture for 12h.(I) Flow cytometric analysis and Immunofluorescent staining showed 
accumulation of Gr-1+CD11b+ neutrophils in the tumor (I, left) expressing IL-21 (I, upper right). 
Immunoblot analysis showed p38 MAPK auto-activation in neutrophils from Becn1ΔM tumor-
bearing mice (I, lower right). (J) Fluorescent microscopy (left) and statistical (right) analysis of 
NETs formation in WT and Becn1-deficient neutrophils by using SYTOX impermeable nuclear 
dye (green). White arrows (Original magnification, x40) indicate NETs. (K) Immunofluorescence 
of tumor section with anti-Ly6G (red), CXCR3 (green), and DAPI (blue) from Becn1ΔM tumor-
bearing mice compared to WT controls showing colocalization of Ly6G and CXCR3 in tumor but 
not WT control LN.(L) Immunohistochemical staining of tumor sections Becn1ΔM tumor-bearing 
mice with anti-CXCL9 antibody compared to WT control LN. Data shown are plotted as the mean 
± s.d. and are representative of three independent experiments. *P <0.05, **P <0.01, ***P <0.001, 
NS (not significant) vs. corresponding control.   
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Neutrophil loss of Becn1 transforms pre-B cells through prosurvival pathways correlating with 
human pre-B ALL 
To determine how the neutrophil loss of Becn1 contributes to the malignancy of B cells, 
RNA-seq was performed using freshly isolated total B cells from WT and Becn1ΔM tumor-bearing 
mice. Significant upregulation of genes included:  1) STAT target genes such as Cxcl9, Socs1, 
Socs3, Irf1 and Cd274 (PD-L1); 2) precursor B (pre-B) cell markers such as IL2ra and Ly6a [171]; 
3) B cell activation markers such as IL10 and Saa3; 4) MHC class I related molecules such as 
Nlrc5 and Psmb9; and 5) the innate immunity gene Mb21d1 (cGAS) (Figures 18A and 18B).  
We next sought to examine whether tumor cells had altered oncogenic signalings [147, 
172]. The tumor cells and control cells were sorted by B220+ selection followed by immediately 
lysed or anti-CD40 agonist stimulation. We observed increased activation of ERK and JNK, 
elevated activation of signaling downstream of IL-21 (STAT1, STAT3, STAT5) and BAFF (non-
canonical NF-κB p52), as well as upregulated STAT5-target (anti-apoptotic gene MCL-1) [173] 
(Figures 18C and 18D). Moreover, we compared signaling activations in B cells from WT, tumor-
free Becn1ΔM (NT), and B220hi vs. B220lo cells from tumor-bearing Becn1ΔM mice. We found 
B220lo cells showed a higher level of phosphorylated STAT1/3/5 and PD-L1 than B220hi cells 
(Figures 18D and 18E). By co-culturing neutrophils or macrophages from tumor-bearing Becn1ΔM 
mice with normal WT B cells, we confirmed the induction of p-STAT3 and PD-L1 in B cells by 
neutrophil-derived IL-21 (Figure 18F) and could be abolished by either IL-21 antibody blockade 
and p38 ablation (Figures 18G-I). In Figures 13 and 15, we showed p38 signaling regulated 
neutrophil inflammation in Becn1ΔM mice in response to TLR ligand stimulation, which was auto-
activated in tumor-derived neutrophil (Figure 17I). We next examined if ablation of p38 reduce 
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the risk of B cell lymphoma in Becn1ΔM mice. Indeed, myeloid loss of p38 suppressed tumor 
formation in Becn1ΔM mice (Figure 18J). 
To investigate whether Becn1 in human neutrophils play a role in human B-cell lymphoid 
malignancies, we first analyzed Becn1 expression in a series of human B-cell non-Hodgkin 
lymphomas (B-NHL) and pre- B cell acute lymphoblastic leukemia/lymphoma (ALL) by human 
gene expression profiling (GEP). Becn1 expression varied among the different B-cell lymphoid 
malignancies, with significantly lowest in pre-B ALL and highest in MCL and CLL (Figure 18K). 
We further detected Becn1 expression in neutrophils in 8 human pre-B ALL patients, and we found 
low Becn1 expression in neutrophils compared to reactive lymph node controls (Figures 18L and 
18M). Notably, in recurrent pre-B ALL patient, Becn1 low neutrophils had the NET-like structure 
(Figure 18L). Consistent with the upregulation of PD-L1 in B cells in Becn1ΔM mice, we found 
upregulation of PD-L1 in pre-B ALL patient BM and LN samples especially in recurrent pre-B 
ALL samples (Figure 18N). These data suggest defective Becn1 in neutrophils might have a direct 
link to the PD-L1 levels and recurrence in human pre-B ALL. To apply our findings and to examine 
the tumor immunity in mouse model of melanoma, we injected intravenously the B16 melanoma 
cells. In Becn1ΔM mice, we observed dramatic increase in melanoma cell metastasis in the liver but 
slightly increase in the lung (Figure 18O).  Interestingly, we found infiltrations of neutrophils with 
NET structure and PAX5 positive B cells in metastases accompany by reduced number of T cells 
(Figures 18P). Thus, our results suggest that the accumulation of neutrophils and PD-L1+ B cells 
in liver might establish niches for melanoma metastasis and potentially suppress anti-tumor 
immunity through immune checkpoint inhibition. 
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Figure 18. Neutrophil inflammation favors the malignancy of PD-L1+ pre-B cells. (A) 
Heatmap representation of genes significantly upregulated in B cells isolated from Becn1ΔM tumor-
bearing mice compared to WT controls by RNA-seq. (B) Quantitative RT-PCR for analysis of the 
mRNA levels of the indicated genes in B cells from WT, Becn1ΔM (N, no tumor), and Becn1ΔM (T, 
tumor-bearing) mice (n=4 per group). (C) Immunoblot analysis of phosphorylation of ERK, JNK, 
IKK and p38 in total B220+ cells isolated from WT control and from Becn1ΔM tumor-bearing mice 
stimulated with anti-CD40 agonist for indicated time points. (D) Immunoblot analysis of PD-L1, 
p-STAT1, p-STAT3, p-STAT5, MCL-1 and p52 in B cells isolated from WT control, Becn1ΔM 
mice without palpable tumor (NT) and Becn1ΔM tumor-bearing mice (T-B220hi vs. T-B220lo cells).  
(E) Immunofluorescent staining of tumor sections with PD-L1 (red) and B220 (green) antibodies 
compared to WT controls, showing upregulation of PD-L1 in B220lo cells (dark green) compared 
to B220hi cells (bright green). (F) Neu or pMAC isolated from WT or Becn1ΔM tumor-bearing mice 
were co-cultured with WT B cells. After co-culture for 24h, B cells were purified and lysed for 
immunoblot analysis with indicated antibody. Two representative samples were shown. (G) B cells 
isolated from WT, Becn1ΔM tumor-bearing mice, and Becn1ΔM x Mapk14 ΔM mice were purified 
and lysed for immunoblot analysis with indicated antibody. (H) Neutrophils isolated from WT or 
Becn1ΔM tumor-bearing mice were co-cultured with WT B cells (Neu/B co-culture) together with 
Mock antibody treatment, anti-IFN-γ, anti-IL-1β, anti-CD40L, anti-IL-21, or B cells without 
neutrophils (B only).  After co-culture for 24h, B cells were purified and lysed for immunoblot 
analysis with indicated antibody. Quantitative comparisons of pSTAT3 and PD-L1 level were 
analyzed by densitometric scanning of blots and normalized to β-actin (right). (I) ELISA assay of 
the IL-21 production in neutrophils from WT, Becn1ΔM tumor-bearing mice, and Becn1ΔM x 
Mapk14 ΔM mice. n=10. (J) Kaplan-Meier curves for tumor-free animals were calculated based on 
the tumor latency of the WT (n=10, black), Becn1ΔM mice (n=10, red) and Becn1ΔM x Mapk14 ΔM 
(n=10, blue) mice. (K) Human Becn1 gene expression profile (GEP) in patients with pre- B cell 
acute lymphoblastic leukemia (pre-B ALL, without mutations or gene rearrangements) or various 
non-Hodgkin’s B cell (NHB) lymphoma compared to reactive lymph node controls. The boxes 
show the median±1 quartile, with whiskers extending to the most extreme data point within 1.5 
interquartile range from the box boundaries. (L) Becn1 expression analysis by IF staining in human 
neutrophils in human normal reactive lymph node controls and pre-B-ALL patient samples 
including patient with recurrence of pre-B-ALL (no genomic mutation or gene rearrangement). 
(M) Quantification of Gr-1+ Becn1-expressign cells in reactive lymphoid hyperplasia and pre-B 
ALL patient samples (n=6). (N) Immunoblot analysis of PD-L1 expression in pre-ALL patient BM 
and LN samples compared to normal controls. (O) Liver metastasis of melanoma in WT and 
Becn1ΔM mice i.v. injected with 2x105 cells per mouse of B16 cells. (P) Cell number counting per 
tumor-field and statistical analysis of B16 liver metastases, infiltrated CD3+ T cells (TIT), PAX5+ 
B cells (TIB), Gr1+ Neutrophils (TIN), and F4/80+ (TIM) in B16 melanoma-bearing WT and 
Becn1ΔM mice (n=10). 
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Discussion 
Despite numerous in vitro studies emphasizing a role for autophagy in macrophages during 
Mycobacterium tuberculosis infection or LC3-associated phagocytosis [89, 174], little is known 
about the function of Becn1 in neutrophils in inflammation and cancer in vivo. We have 
demonstrated that deletion of Becn1 in the myeloid lineage leads to neutrophilia, which causes 
splenomegaly and lymphadenopathy in mice. We uncovered a cell-type specific mechanism of 
Becn1 in the negative regulation of neutrophil p38 signaling in response to LPS. Depletion of 
neutrophils but not macrophages rescued the sensitivity of Becn1ΔM mice to LPS endotoxin shock, 
suggesting an excessive LPS-induced neutrophil inflammation. Our cytokine profiling and RNA-
seq results further revealed the enhanced productions of TNF-α, IL-1β, ROS, IL-17-related 
cytokine, and chemokine-receptor Cxcr3 by neutrophils in Becn1ΔM mice. p38 MAPK signaling is 
critical for the transcription and production of inflammatory cytokines [175-177]. Consistent with 
the cell depletion results, we have provided compelling genetic evidence that p38 (encoded by 
Mapk14) ablation in myeloid cells rescues the observed phenotypes and the production of 
inflammatory cytokines in Becn1ΔM mice. Although we have found an elevated production of IL-
6 by macrophages, IL-6 ablation failed to rescue the survival of Becn1ΔM mice to LPS.  
It is known that MAP3Ks (TAK1, ASK1, MEKK3) activation triggers downstream 
signaling of IKK complex, Erk1/2, p38, and JNK [34]. We show that Becn1 interacts with MEKK3 
and MKK3 and promotes MEKK3 K48 ubiquitination at lysine 299 and subsequently proteasomal 
degradation independent of autophagy. Due to the low protein level of MEKK3 observed in 
neutrophils, stabilization of MEKK3 upon Becn1 deletion leads to aberrant activation of MEKK3-
MKK3-p38 signaling axis in neutrophils. Further ablation of MEKK3 has significantly prolonged 
the survival of Becn1ΔM mice to LPS.  
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Heterozygous deletion of Becn1 in mice increases the incidence of spontaneous tumors 
including diffused large cell b-cell lymphoma (DLBCL) [142, 143], suggesting that Becn1 is a 
haploinsufficent tumor suppressor. However, it is unclear whether the tumor formation is 
contributed by intrinsic factors or transformed by oncogenic inflammation induced by non-
transformed immune cells in the tumor microenvironment. In Becn1ΔM mice, we unexpectedly 
found immature Pax5+TdT+B220lo-int pre-B cell infiltrating into major organ tissues and high risk 
of pre-B cell lymphoma formation at the early age of 15-25 weeks. Becn1-deleted neutrophils, but 
not macrophages, were constantly found to colocalize and interact with B cells in secondary 
lymphoid tissues and other infiltrated organ tissues. Stromal cells, Bruton’s tyrosine kinase, 
S1P/S1P receptor, CXCL12/CXCR4 signaling cascades, and α4β1-VCAM-1-mediated adhesion 
regulate B cell migration from bone marrow [170, 178-181]. Downregulation CXCR4 and cell-
cell adhesion molecules such as claudins in the tumor may favor the B cell migration and 
neutrophil-B cell interaction.  
Recent studies identify a unique population of IL-21 secreting neutrophils termed B cell 
helper neutrophils to sustain B cell survival, expansion and malignant transformation  [167, 168, 
170]. However, mechanisms underlying the differentiation and transition of neutrophils to gain “B 
cell helper” function is unknown. Notably, neutrophils isolated from Becn1ΔM tumor-bearing mice 
were p38 auto-activated and showed upregulated “B helper” signatures including IL-21, BAFF, 
CD40L, and production of NET. These factors have been shown to activate multiple oncogenic 
signaling, including STAT and non-canonical NF-kB known to be crucial in initiating oncogene 
transcription and establishing the tumor pre-metastatic niche [148, 172, 182-184]. Intriguingly, 
our RNA-seq and qPCR results confirmed the expression of pre-B cell marker Il2ra and Ly6a, PD-
L1, and Irf1, an essential transcription factor mediated STAT signaling and the expression of both 
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PD-L1 and MHC-I molecules [69, 185, 186]. Strikingly, when comparing B220lo with B220hi cell 
populations, we observed specifically in B220lo cells the persistent activation of STAT1, STAT3, 
STAT5, and non-canonical NF-κB p52, followed by upregulation of their downstream targets 
MCL-1, chemokine Cxcl9, and checkpoint inhibitor PD-L1. Importantly, we have further 
unraveled a positive feedback recruitment of neutrophils by pre-B cells through the Cxcl9-Cxcr3 
chemotaxis to promote malignant transformation of pre-B cells (Figure 19).  
Based on our findings in mice, we also found downregulation of Becn1 in pre-B ALL 
patients without gene mutations and gene rearrangements. Becn1 low expression in neutrophils 
correlates with PD-L1 levels and cancer recurrence in patients with pre-B ALL, which 
recapitulated the malignant pre-B cells identified in Becn1ΔM mice. PD-L1 is one of the most 
essential checkpoint inhibitory mechanisms utilized by tumor cells or other immune suppressor 
cells to suppress T cell function for immune evasion [67-69, 187]. Recent studies of the PD-L1-
expressing IgA+ B cells have been shown to suppress CD8+ T cells killing of liver tumor in mouse 
model of inflammation-induced liver cancer [71]. By utilizing a mouse model of B16 metastatic 
melanoma, we found dramatic increase of liver metastasis of B16 melanoma cells, accompanied 
with the enrichment of tumor-associated neutrophils and B cells. Together these data demonstrate 
a tumor suppressor role of myeloid Becn1 in pre-B tumor progression and provide evidence to 
support possible roles of tumor-associated neutrophils and B cells in melanoma metastasis. 
Neutrophil Becn1 inhibition might sensitive the metastatic and/or recurrent pre-B ALL to PD-L1 
antibody blockade therapy.  
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Figure 19. Schematic diagram illustrates neutrophil Becn1 in pre-B cell malignancy. Cartoon 
indicates Becn1-deficient neutrophils gain the B cell helper function: enhanced expression of 
CD40L, secretion of pro-survival factors IL-21, BAFF, and NET. The interaction of Becn1-
deficient neutrophils and B cells through CXCL9-CXCR3 chemotaxis, leading to the activations 
of STAT1/3/5, ERK, JNK, and non-canonical NF-κB pathways and malignancy of pre-B cells. 
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CHAPTER IV  
CONCLUSIONS 
 
Mankind has evolved to combat viruses by developing a robust and tightly controlled viral 
sensing system. By coupling APEX-proteomic mapping and yeast-two hybrid screening, we 
identified a previously unrecognized mitochondrial WHIP-TRIM14-PPP6C signalosome. WHIP 
is the key mediator coupling the RIG-I sensor to the mitochondrial TRIM14 signalosome allowing 
RIG-I translocation to mitochondria where RIG-I and MAVS interact. PPP6C, on the other hand, 
maintains the dephosphorylation status of RIG-I leading to optimal activation of the antiviral type 
I IFN response. PPP6C is one of the hotspot mutations in melanoma. Our study of PPP6C in the 
regulation of IFN signaling might provide immunotherapeutic insight into the treatment of 
melanoma patients.  In this study, we reveal a dual role of TRIM14 in mediating both viral DNA 
and RNA sensing pathways through distinct mechanisms as in our previously reported that 
TRIM14 stabilizes cGAS through recruitment of USP14 for K48 deubiquitination. Our study also 
raises a possibility that viruses such as West Nile virus, dengue virus, or influenza virus manipulate 
the TRIM14 signalosome to benefit their replication as viral evasion strategy. The WHIP-
TRIM14-PPP6C might also be a potential therapeutic target for efficacious antiviral drug 
development.  
Most of the studies of Becn-1 so far are done in heterozygous mice due to embryonic 
lethality of Becn-1 general knockout in mice. For this particular shortcoming, the specific roles of 
Becn-1 in terminally differentiated cells and the underlying mechanisms that contribute to the 
tumorigenesis or tumor-suppression are not well defined. Our characterization of myeloid beclin1 
in genetic mouse model gains an overall picture of how innate immune system interplays with 
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adaptive immunity. Combining a new myeloid-specific deletion of Becn-1 mouse model and next-
generation sequencing, we understand how the status of Becn-1 in innate immune cells contributes 
to tumorigenesis and provide a clear explanation on the intense discussion of the contradicted role 
of autophagy proteins in cancer progression. Our study suggests a correlation between low 
expression of myeloid Beclin1 and the risk of human pre-B ALL, hinting the use of 
pharmacological inhibitors of autophagy in the treatment of cancer especially those targeting 
Beclin1 might have a potential risk of causing chronic inflammation and lymphoid malignant 
transformation. On the other hand, upregulation of PD-L1 expression on B cells resulting from 
myeloid Beclin1 ablation might inhibit the cytotoxic function of antitumor CD8+ T cells in tumor 
microenvironment through checkpoint inhibition. In such case, PD-L1 antibody blockade might 
induce tumor regression. Our study provides a mechanism for better therapeutic drug development 
that not only cures cancer but also prevents the cause of chronic inflammation that may potentially 
fuel the cancer recurrence in patients exposed to long-term treatment. The study of tumor 
microenvironmental Beclin1 such that in MDSCs also contributes to the mechanism of how tumor 
cells escape from checkpoint blockade immunotherapy, which is critical for enhancing the efficacy 
of combination immunotherapy.  
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